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The vasculature in the brain is formed by brain microvascular endothelial cells (BMECs) 
surrounded by pericytes and astrocytic endfeet.  Together these cellular components constitute the 
blood-brain barrier (BBB) and regulate transport into and out of the brain.  BMECs possess intrinsic 
barrier properties to regulate transport, including enriched expression of tight junctions (TJs) which 
block paracellular transport, efflux pumps which limit transcellular transport, and nutrient 
transporter systems which increase substrate transcellular transport.  In healthy individuals, these 
properties limit the passage of ~98% of small molecules into the brain, representing a major hurdle 
for brain disease treatment.  However, during some brain diseases the BBB displays structural and 
functional alterations which can directly contribute to disease progression.  In this work, tissue-
engineered three-dimensional (3D) brain microvessels are developed to enable studies of the BBB 
during health and disease.  Key advantages of 3D microvessels compared to two-dimensional 
assays (i.e., transwells) are established, including recapitulation of critical microenvironmental 
cues present within the native BBB (i.e., cylindrical geometry, cell-matrix interactions, and shear 
flow), physiological permeability, and high spatiotemporal resolution.  Chapter 1 provides an 
overview of brain microvascular plasticity; this overview highlights processes that are later studied 
within our 3D microvessel models.  Chapter 2 describes the tissue-engineering approach to form 
3D microvessels by seeding induced pluripotent stem cell (iPSC)-derived BMECs into ~150 μm 
diameter channels patterned within type I collagen.  This model is used to study: (1) brain 
specificity of barrier function, (2) efflux inhibition, (3) cytokine response, and (4) the influence of 
neurodegenerative mutations.  Chapter 3 describes a study on the mechanisms of enhanced drug 
delivery using hyperosmotic BBB opening.  The hyperosmotic agent mannitol results in dose-





of transient focal leaks; additionally, the susceptibility to opening and subsequent repair is 
modulated by growth factor treatment.  Chapter 4 describes a bead assay and tissue-engineered 
microvessel model of brain angiogenesis used to study the influence of chemical and physical 
factors on angiogenic phenotype.  Together these works show that tissue-engineered BBB 
microvessels can provide insight into the mechanisms of drug delivery and various brain disease 
states. 
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Chapter 1. Cerebrovascular plasticity: processes that lead to changes in the 
architecture of brain microvessels 
A version of this chapter is published in Journal of Cerebral Blood Flow & Metabolism 39 (2019) 
1413-1432. [1] 
Max I. Bogorad,1,2,† Jackson G. DeStefano,1,2,† Raleigh M. Linville,1,3,† Andrew D. Wong,1,2,4,†  
Peter C. Searson1,2 
1 Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, MD  
2 Department of Materials Science and Engineering, Johns Hopkins University, Baltimore, MD 
3 Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 
† These authors contributed equally to this work 
1.1. Introduction   
The brain has no moving parts and yet it is one of the most energy expensive organs in the body, 
consuming 15 - 20 watts [2, 3].  To power the adult human brain, nutrients are supplied to the 100 
billion neurons via a 600 km network of capillaries and microvessels [4].  Since the brain does not 
have significant capacity to store metabolic nutrients, cerebral blood flow (CBF) is generally 
proportional to cerebral metabolic rate [5], and the cell bodies of neurons are typically 10 - 20 µm 
from the nearest capillary [3].  Therefore, the cerebrovasculature is crucial to maintenance of 
normal brain function.   
The cerebrovasculature, in addition to supplying nutrients and other essential molecules, is a key 
component of the blood-brain barrier (BBB) which maintains tight control of the brain 
microenvironment by regulating fluctuations in chemistry, transport of immune cells, and the entry 
of toxins and pathogens [3, 6].  Under homeostatic conditions, the turnover of brain microvascular 
endothelial cells (BMECs) is very low and the cerebrovascular architecture is considered to be 










perturbations to the cerebrovasculature and the neuronal architecture are closely related.  The 
cerebrovascular architecture displays profound plasticity during development, aging, injury, and 
disease (Figure 1-1).  
Transient changes in neural activity can be accommodated by local dilation or contraction of 
arterioles and capillaries.  However, sustained changes in the global brain microenvironment, for 
example due to sensory deprivation or hypoxia, can lead to robust remodeling of the 
cerebrovascular architecture.  At the cellular level, changes in the cerebrovascular architecture 
involve changes in the rates of proliferation and loss of BMECs that are associated with addition 
or subtraction of capillary segments.  As a result of neurovascular coupling, these changes are 
usually closely associated with local gain or loss of neurons and may ultimately be associated with 
changes in cognitive function.  Although cerebrovascular plasticity is observed at all hierarchical 
levels, here we focus on the microvasculature (arterioles, capillaries and venules). 
The time scales of these process span a wide range.  For example, changes in CBF in response to 
increases in neural activity occur with a time constant on the order of seconds.  Changes in 
cerebrovascular architecture due to sustained sensory deprivation or hypoxia, occur with time 
constants of several weeks.  The cerebrovasculature displays elevated plasticity during 
development, while during aging plasticity declines.  The time scale of changes during development 
and aging is on the order of months to years, where the rate often depends on mitigating factors 
such as exercise (in the case of aging).  Injury can result in rapid damage to cerebrovascular and 
neuronal architecture, followed by partial or complete repair over weeks to months.  In contrast, 
neurodegenerative disease is characterized by highly heterogenous changes that occur over months 











Figure 1-1. Cerebrovascular architecture displays profound plasticity during the human 
lifespan.A summary of changes during: (A) development, (B) homeostasis, and (C) aging, injury, 
and disease.  (D) Microvascular density increases via angiogenesis in the brain.  Shown is the mouse 
postnatal cortex, arrowheads denote endothelial sprouts [7]. (E) The blood-brain barrier (BBB) 
displays functionally low permeability during early stages of brain development; here, a guinea pig 
embryo injected with trypan blue demonstrates restriction of dye entry into CNS [8]. (F) 
Neurovascular coupling is the process by which increases in neural activity create changes in local 
cerebral blood flow and cerebral consumption of oxygen; here, we display a change in local total 
hemoglobin concentration (dark red) in response to electrical stimulation in the somatosensory 
cortical surface of a rat [9].  (G) Chronic hypoxia results in increased microvascular density in the 
mouse motor cortex [10]. (H) TBI results in a rapid decrease in microvascular density in rats [11].  
(I) During Alzheimer’s disease, the most common neurodegenerative disease, amyloid-beta 
accumulates around human microvessels and BBB integrity is compromised (downregulation of 
the tight junction protein claudin-5) among other cerebrovascular changes [12].   
 
1.2.Cerebral Blood Supply and Metabolism 
1.2.1. Cerebral blood supply 
The brain receives blood supply from the cerebral branches of the internal carotid (which then 
branch into the anterior and middle cerebral arteries) and the vertebral arteries (that later merge to 










are interconnected in the cranial cavity to produce the Circle of Willis, which creates collateral 
circulation.  If any parts of the Circle of Willis or supplying arteries become blocked or narrowed, 
blood flow remains at least partially preserved by the other supplying vessels, reducing the 
likelihood of ischemia.  Anastomoses also occur between the branches of the three cerebral arteries 
on the surface of the brain.  In adults, if one of the four arteries delivering blood to the brain is 
blocked, the remaining three are not usually capable of providing adequate circulation, resulting in 
ischemic stroke [14].  Additionally, cerebral blood supply reflects the metabolic demands of 
specific brain regions and defines their susceptibility to vascular damage.  For example, regions 
that are supplied by a single major artery and have a continuous capillary network with weak 
collateral flow are at higher risk for hypoxic injury and stroke [15].   
1.2.2.Cerebral blood flow (CBF) 







where ∆P is the pressure gradient per unit length of vessel (l), r is the vessel radius, and µ is the 
dynamic viscosity.  The Poiseuille equation can be simplified in terms of the cerebral perfusion 
pressure (CPP = ∆P) and the cerebrovascular resistance (CVR).  The cerebral perfusion pressure is 
the difference between the mean arterial pressure (MAP) and the intracranial pressure (ICP).  In 
adults, the ICP is normally 5 - 15 mm Hg when supine.  Sustained ICP values in excess of 20 - 25 
mm Hg are considered to indicate risk for focal ischemia.  The average CBF is about 50 mL per 
100 g of brain tissue per minute (750 mL min-1 for an adult) [13].  Blood flow is about twice as 
high in grey matter due to the higher density of neuronal cell bodies.  In contrast, blood flow in 











Figure 1-2. Cerebrovascular architecture.  (A) Arterial architecture. (i) Inferior view of the base 
of the brain with cerebral arterial Circle of Willis. (ii) Magnified view of the Circle of Willis.  (iii) 
Right lateral view of the right hemisphere. (B) Microvasculature ultrastructure in the cerebral 
cortex. (i) Schematic illustration of the vasculature in the cerebral cortex showing both arterial and 
venous systems. Pial arteries located on the surface penetrate deep into the cerebral cortex as 
penetrating arterioles, which branch into capillary beds that then reemerge from the cortex as 
ascending venules [9].  (ii) Scanning electron micrograph of a corrosion cast showing the 
vasculature of the temporal lobe of the human cerebral cortex [17]. (Scale bar = 375 µm) (1) Pial 
artery, (2) long cortical artery, (3) middle cortical artery, (4) short cortical artery, (5) cortical vein, 
(6) subpial zone, (7) precapillary vessel with blind ending, (8) superficial capillary zone, (9) middle 
capillary zone, and (10) deep capillary zone.  (C) Neurovascular unit. (i) Schematic illustration of 
the neurovascular unit comprised of brain microvascular endothelial cells surrounded by pericytes 
and astrocytes [7]. (ii) Electron microscope cross section of a capillary from the rat frontoparietal 
cortex [18]. BM – basement membrane. BMECs – brain microvascular endothelial cells. TJ – tight 











CBF is maintained at a relatively constant value over a range of cerebral perfusion pressures (50 - 
150 mm Hg) by autoregulation: changes in CPP are compensated by changes in artery diameter 
(vasodilation or vasoconstriction) [13, 19].  The lower limit corresponds to the point of maximum 
dilation and at lower pressures the CBF decreases with decreasing pressure due to vessel collapse. 
The upper limit corresponds to maximum constriction and higher pressures result in disruption of 
the BBB [16].  Autoregulation is maintained through multiple mechanisms including metabolic 
(e.g. CO2 levels), myogenic (e.g. nitric oxide) and neurogenic (e.g. sympathetic innervation) 
regulation [19].   
The average cerebral blood volume (CBV) is 3.5 - 4.5 mL per 100 g tissue (about 50 mL for an 
adult brain) [20].  A large fraction of this volume is contained in the venous sinuses and pial veins.   
Although the CBV is a small fraction of the brain vol (around 4%), it plays an important role in 
regulating intracranial pressure since it can be modulated very quickly by changing the blood flow.  
Since CBV ∝ r2 and CBF ∝ r4 (see above) it is predicted that CBV ∝ CBFn where n = 0.5 [21].  
Studies in humans and animals have reported exponents of 0.3 - 0.4 [21]. 
1.2.3.Cerebral metabolism 
The brain is one of the most energy expensive organs in the human body.  Overall the brain accounts 
for 15 - 20% of the base metabolic rate, consuming 15 - 20% of oxygen leaving the heart and 15 - 
20% of the glucose consumed daily [2, 3].   Since the brain does not have significant capacity to 
store metabolic nutrients, fuel to power the brain is provided on-demand by the lungs and GI system 
which transfer oxygen and glucose, respectively, to the vascular system.   Glucose is transported 
into the brain by glucose transporter 1 (GLUT1) localized to BMECs, while oxygen passively 












Neuronal architecture, and thus cerebrovascular architecture, is spatially heterogeneous [13, 22].  
In the cerebral cortex, pial arteries on the brain surface descend to become parenchymal arterioles 
to supply microvascular beds of cortical grey matter (Figure 1-2, B) [9].  At the interface between 
gray and white matter, the microvascular density decreases substantially along with the density of 
neurons and other supporting cells.  In white matter, capillaries are generally arranged in parallel 
with axons and microvascular density is roughly 10% of that in the grey matter (consistent with the 
lower blood flow) [13, 22].  Pathological and physiological stresses can promote increases or 
decreases in microvascular density via angiogenesis or apoptosis, as addressed in subsequent 
sections.  
In mammals, capillaries have a diameter that is slightly larger than red blood cells [23], which in 
humans corresponds to 8 - 10 µm in diameter.  In the human brain, capillaries have branch points 
approximately every 30 µm, and an inter-capillary spacing of ~50 µm [17].  Venular capillaries in 
the mouse cortex are up to 20 branches away from penetrating arterioles [24], and the average path 
length of RBCs through a single capillary network in the cortex (where flow can be visualized in 
real time by two-photon microscopy) is 150 - 500 µm [25].  Wall shear stress in the capillaries 
ranges from 20 - 40 dyne cm-2 and is regulated by capillary tone via neurovascular coupling [26].  
Downstream from capillaries, post-capillary venules (PCVs) have a perivascular space that serves 
as a preferential site for extravasation of leukocytes, tumor cells, and parasites [27-29].  PCVs have 
an average wall shear stress from 1 - 4 dyne cm-2, and smaller cardiac cycle-based fluctuations 










1.3.2.The neurovascular unit  
The neurovascular unit, which comprises the blood-brain barrier (BBB), embodies the system that 
regulates neurovascular coupling.  The cellular components of the BBB are brain microvascular 
endothelial cells (BMECs), pericytes, and astrocytes, and implicitly include neurons in the context 
of coupling (Figure 1-2, C) [6, 26].  Highly specialized BMECs provide the physical barrier 
between the vasculature and brain parenchyma.  Pericytes are mural cells with a round nucleus and 
long processes that extend along the abluminal endothelial wall.  A basement membrane (BM), 
composed of collagen IV, laminin, nidogen and heparan sulfate proteoglycans surrounds BMECs 
and pericytes [3].  Astrocytes are star-shaped glial cells with small cell bodies and long radial 
processes that contact both synapses and the BM.  In capillaries, endothelial cells, pericytes, and 
BM are completely surrounded by astrocytic end-feet [30].  Astrocytes serve multiple functions in 
the brain, including spatiotemporal modulation of local blood flow by relaying signals from 
neurons to BMECs via their end-feet to induce dilation and contraction [30, 31]. 
1.4.Cerebrovascular and Neuronal Plasticity 
Under homeostasis, the cerebrovascular architecture is assumed to be fixed, with very low cell 
turnover.  Direct evidence for cerebrovascular plasticity comes from two-photon microscopy 
studies in animal models [32-35].  In the somatosensory and motor cortex of mice, increases in 
capillary length and the number of branch points have been observed up to post-natal day 25.  
However, in adult mice there was negligible change in capillary segment diameter, capillary 
segment length, or the position of branch points over about 30 days [32, 33].  These results imply 
that there was no turnover in BMECs during the imaging period.  The subtraction or pruning of 
redundant capillary sections in short vascular loops occurred once every 6.25 days per mm3 in the 










could contribute to pathological processes such as vascular atrophy, rarefaction, wall degeneration, 
and the neurodegeneration observed in aged animals [32, 36].  
Increases in microvascular density occur by formation of capillaries from existing blood vessels 
(angiogenesis), or organization of proliferating precursor cells into new blood vessels 
(vasculogenesis).  Angiogenesis involves endothelial cell activation, proteolytic degradation of BM 
and matrix, migration, alignment, proliferation, tube formation, and anastomosis with other vessels.  
During maturation, capillaries develop tight intracellular junctions, produce BM, and recruit 
pericytes and astrocytic end-feet.  Arterioles recruit a layer of smooth muscle cells (SMCs), which 
allows control of vessel tone.  Vascular endothelial growth factors (VEGF) and their respective 
receptor tyrosine kinases (VEGFR) are key regulators of angiogenesis and are inducible in many 
cell types, including astrocytes, pericytes, and endothelial cells [30].  VEGF-A also supports 
neurogenesis, nerve migration, axonal guidance, and neuronal survival [37].  During adulthood, 
brain angiogenesis is observed in response to stimuli such as hypoxia, injury, or neurodegenerative 
disease, as discussed in subsequent sections.  Additionally, vasculogenesis  can occur in response 
to stimuli such as trauma or tissue hypoxia as endothelial progenitor cells (EPCs) are mobilized 
from bone marrow to participate in endothelial cell repair/regeneration and tissue 
neovascularization processes [38].  For example, a higher concentration of circulating EPCs during 
the first week after stroke onset is associated with improved patient outcomes [39].  Cerebral 
arteries also display profound plasticity; for example, during hypertension (elevated blood 
pressure) extensive remodeling of arterial walls occurs to reduce lumen diameter [40].  In 
subsequent sections, we consider the cerebrovascular plasticity of microvessels (arterioles, 
capillaries and venules). 
Neuronal plasticity is distinct from cerebrovascular plasticity in terms of location. In adulthood, 










the hippocampus, and the subventricular zone [41].    These specialized regions are  often referred 
to as neurovascular niches since the vasculature has been identified as a crucial component of the 
stem cell environment [42].  In the subventricular zone, neural stem cells directly contact blood 
vessels in homeostasis as well as regeneration [43], a feature unique to this region of the brain.  It 
has also been shown that new neurons are born in close proximity to blood vessels in the 
hippocampus [44]. 
1.5.Factors that Influence Cerebrovascular Plasticity 
1.5.1.Neural Activity 
A key feature of brain metabolism is the tight coupling between energy supply and demand, 
commonly known as neurovascular coupling or functional hyperemia [31].  Local increases in 
neural activity are followed by dilation of local capillaries and upstream arterioles, increasing CBF, 
and increasing cerebral metabolic rate of oxygen consumption (CMRO2) [9, 16].  This response is 
modulated by secretion of vasodilators, such as nitric oxide (NO), vasoactive intestinal polypeptide, 
and prostaglandin  by endothelial cells, neurons, and other glial cells [31, 45].  Recently, 
extracellular K+, a byproduct of neural activity, has been shown to induce a retrograde 
hyperpolarization signal from capillaries to arterioles, resulting in dilation [46].  These chemical 
factors typically act by promoting relaxation of SMCs surrounding upstream arterioles.  There have 
been contradictory reports on the role of pericytes in dilation and contraction of capillaries [47-50].  
Increased metabolism, which follows an increase in neural activity, is quantifiable though the 
measured increase in CMRO2 [51, 52].  The response to increased neuronal activity is relatively 
fast with changes in CBF occurring within a few seconds [53].   
Neuronal activity results in increases in CBF and CMRO2, with CBF increasing 2- to 4-fold more 
than CMRO2 [52, 54].  Local changes in oxygen consumption result in downstream changes in the 










dependent (BOLD) contrast functional MRI (fMRI) [55-57].  Changes in the concentration of 
deoxygenated hemoglobin are most prevalent in the venous tree following consumption of 
oxygenated hemoglobin in capillaries [58].  
Cerebrovascular architecture is maintained during neurovascular coupling.  However, persistent 
changes in neural activity or nutrient supply can lead to adaptions that include remodeling of 
cerebrovascular architecture.  Examples of such changes are sensory deprivation and hypoxia. 
1.5.2.Sensory Deprivation 
Evidence for coupling between neural activity and cerebrovascular architecture comes from 
sensory deprivation studies in rats and studies of the effect of single eye vision depravation in cats 
[59-62].  Juvenile rats raised in stimulating, complex environments for 30 days were found to have 
increased density of capillary branch points, increased capillary surface area per unit tissue volume, 
and increased number of branch points per unit of capillary surface area within the striate cortex 
when compared to rats in non-complex environments [59, 60].  Similar studies have shown further 
increases in microvascular density in the cerebellar cortex of adult rats, while learning tasks 
increased the number of synapses per unit area [61].  Adult rats raised in complex environments 
showed increased microvascular density and number of branch points.  New microvessels were 
observed after 10 days with full capillary neovascularization occurring between 30 and 60 days 
compared to animals housed in individual cages.  Juvenile rats raised in the dark for up to 60 days 
showed a lower density of neurons, significantly lower cortical thickness, and lower vessel density 
in the striatum [63, 64].   
Increases in neural activity are associated with increased growth rate in the somatosensory cortex 
in rat models [65].   Increased neural activity induced by whisker stimulation for one week, from 
post-natal day 14-21, resulted in increased microvascular density and the number of branch points 










plucking from post-natal day zero to five resulted in decreased microvascular density and the 
density of branch points at post-natal day 14 [66].  These results indicate relatively fast changes in 
cerebrovascular architecture in juvenile mice. 
1.5.3.Hypoxia 
Since oxygen is essential for normal brain function, transient or sustained decreases in oxygen 
supply can lead to hypoxia and result in changes in the cerebrovascular architecture.  In adulthood, 
local hypoxia is usually associated with injury or disease.  For example, ischemic stroke or 
circulating tumor microemboli can cause local hypoxic regions downstream from occlusion. In 
contrast, changes in the oxygen partial pressure of the environment can lead to global hypoxia in 
the brain.  At sea level where oxygen comprises 21% of the atmosphere, the arterial oxygen partial 
pressure (PaO2) is 75 - 100 mm Hg.  Mild hypoxia usually refers to arterial oxygen partial pressures 
down to 50 mm Hg, corresponding to an atmospheric oxygen concentration of about 10% or 
equivalent to an altitude of about 5,000 m [67].  While mild hypoxia results in numerous adaptations 
including angiogenesis, moderate hypoxia (PaO2 = 35 - 50 mm Hg) can result in cognitive deficits, 
and severe hypoxia (PaO2 < 35 mm Hg) can result in loss of consciousness.   
Acute exposure to mild hypoxia results in an increase in CBV due to vasodilation and an increase 
(up to 2-fold) in CBF which returns to baseline after a few days [67].  The renormalization in CBF 
is associated with an increase in red blood cell volume and hemoglobin concentration, a well-
known response to high altitude training in the field of human performance [68].  Rats subjected to 
chronic mild hypoxia display regional specifies increases in microvascular density; a 3-fold 
increase in density in the hippocampus and striatum was observed over 3 - 4 weeks while other 
brain regions display more modest changes [10, 69].  Increases in microvascular density are driven 










upregulation of VEGF, while declines are achieved via BMEC apoptosis following return to 
normoxia [67].   
1.6.Development and Aging 
1.6.1.Development  
During development the cerebrovasculature is dynamic in structure and function.  Many signaling 
pathways converge to facilitate cerebrovascular plasticity [6, 7].  VEGF-A released by the 
developing neural tube initiates formation of the perineural vascular plexus (PNVP) via 
vasculogenesis.  Next, BMECs invade the brain parenchyma from the PNVP via sprouting 
angiogenesis.  Non-CNS specific signaling pathways (e.g. VEGF-A/VEGFR2) and CNS-specific 
signaling pathways (e.g. Wnt7a/b) guide angiogenesis as well as formation of the BBB 
(barriogenesis) [6, 7].  Cues in the microenvironment that guide angiogenesis and barriogenesis 
display unique temporal and spatial expression profiles.  For example, VEGF-A expression by 
neurons guides early angiogenesis, whereas postnatally, astrocytes surrounding the 
microvasculature are the predominate source of VEGF-A; chronic developmental hypoxia disrupts 
this expression pattern and results in hypervascularization [70].  Wnt/β-catenin signaling is 
uniquely required for CNS angiogenesis and barriogenesis; neural progenitor cells release Wnt 
ligands (Wnt7a and Wnt7b) that guide sprouting of BMECs and induce BBB formation via 
expression of GLUT1[71].  
The timing of angiogenesis and barriogenesis during brain development is controversial.  However, 
accumulating physiological and molecular evidence indicates that the developing brain displays 
barrier properties appropriate for each developmental stage [72].  Studies in zebrafish suggest that 
angiogenesis and barriogenesis are temporally indistinguishable [73], while histological studies in 
human embryos show that during brain angiogenesis capillaries are positive for the tight junction 










remodeling continues but is not well understood; however, VEGF-A and axonal growth inhibitor 
NOGO-A have been implicated [7]. 
As BMECs invade the CNS they interact with neurons, neural stem cells, glial precursors, and 
pericytes.  Sprouting BMECs release PDGF-β to recruit pericytes and initiate BBB formation 
during embryogenesis [75].  Astrocytes are not present in the developing brain when it is initially 
vascularized, however, astrocytic-derived sonic hedgehog ligands are critical in promoting BBB 
integrity and immune quiescence postnatally [76].  Glial-endothelial interactions also guide spatial 
patterning during brain development; radial glia cells provide a scaffold for BMEC migration, 
whereas BMECs later provide a scaffold for oligodendrocytes precursor migration [7, 77].  
1.6.2.Aging 
Aging is associated with heterogeneous decreases in both microvascular and neuronal density in 
the brain.  Although these decreases can be linked, evidence suggests that cerebrovascular plasticity 
and neurovascular coupling are also impaired during aging [36, 78].   Histological analysis of post-
mortem tissue in humans frequently shows a decrease in microvascular density (typically 10 – 30%) 
during normal aging, particularly in the prefrontal cortex and hippocampus [36, 78, 79].  Aging is 
also associated with thickening of the BM, pericyte degeneration/loss, and swelling of astrocytic 
end-feet [78, 80].  Age-associated functional changes include increased tight junction defects and 
increased permeability [81, 82].  Similar age-associated changes have been observed in brain 
arterioles in the cerebral cortex, including decreased density (~40%), loss of SMCs and elastin, and 
gain of BM and collagen [78]. 
Evidence from two-photon microscopy of the cerebral cortex in mouse models showed BMEC 
senescence, reduced turnover, and diminished hypoxia-induced angiogenesis compared to younger 
mice [33].  Similar to other vascular beds, impaired angiogenesis is thought to be related to HIF1-










inactivity, reduced bioavailability of nitric oxide, impairment of endothelial proliferation, reduced 
recruitment of EPCs, and pericyte dysfunction [83].  Enriched environments or administration of 
VEGF viral vectors, which elicit increases in brain microvascular density in juvenile and adult 
rodents, result in reduced changes in aged rodent brains [84, 85].  Age-associated failure of 
angiogenic signaling is implicated as VEGFR-2 is not properly unregulated upon stimulation [85] 
and brain-region specific changes in angiogenesis-related genes are found in aged mice [79]. 
Numerous brain-imaging studies have shown age-associated decreases in CBF and CMRO2 in 
many regions of the cerebral cortex, in particular, in regions vulnerable to neurodegeneration [86].   
In the cortex, decreases of 0.38 to 0.76% per year have been reported [20, 86-88].  Studies of 
healthy brains indicate that decreases in CBF are largely distinct from grey-matter atrophy, 
suggesting that age-associated changes in ultrastructure and hemodynamics are independent [87].  
CBF reductions may result from a loss of arterial supply to the brain (mediated by decreased IGF-
1 [89]), a hypercontractile arteriole phenotype, and impaired neurovascular coupling.  
Neurovascular coupling is impaired during aging in humans and animal models [90-93]. 
Dysfunctional neurovascular coupling causes a mismatch between supply and demand of 
oxygen/metabolites for neurons, likely contributing to cognitive decline.  Interestingly, 
pharmacologically induced cerebrovascular uncoupling in mice mimics the aging phenotype (e.g. 
impaired spatial working memory, recognition memory, and motor coordination) without changing 
basal CBF [94].  The contributions of IGF-1 deficiency, oxidative stress, endothelial dysfunction, 
and astrocyte dysfunction to cerebrovascular uncoupling during normal aging have been reviewed 
elsewhere [93].  Pericyte degeneration has also been implicated in cerebrovascular uncoupling via 
reductions in oxygen delivery and increased metabolic stress [48].  BOLD fMRI studies of neural 
activity during aging are complicated by cerebrovascular changes including the loss of 










technique found no significant change in BOLD neurovascular coupling during visual and auditory 
task with normal aging [96].  Thus it remains unclear if age-associated declines in neural activity 
precede cerebrovascular changes or result from impaired cerebral hemodynamics.  
1.7.Response to Injury and Disease 
Injury and disease result in profound changes in cerebrovascular structure, plasticity, and coupling.  
However, the time scale of these changes are unique.   Stroke and traumatic brain injury (TBI), the 
most common causes of cerebrovascular injury [97], result in immediate loss of cerebrovascular 
architecture, followed by repair responses mediated by the neurovascular unit over weeks to 
months.  Cerebrovascular repair is coordinated by many converging processes that depend on injury 
type and severity [98, 99].  The signaling molecules and transcription factors that regulate these 
processes are often mediators of early vascular injury but may also result in long term repair and 
restoration of normal cerebrovascular function.  During neurodegenerative disease, changes in the 
cerebrovasculature are more gradual and highly dynamic in that disease progression may include 
both increases and decreases in cerebrovascular density (Table 1-1).   Injury and disease display 
interesting epidemiological links; for example, TBI is a risk factor for both stroke [100] and 
neurodegenerative disease [101] 
1.7.1.Ischemic Stroke 
Stroke is the most common form of cerebrovascular injury and second leading cause of death 
worldwide [102].  Each year, roughly 15 million individuals experience stroke worldwide.  Of 
these, one third do not survive while another third become permanently disabled.  The most 
common site of ischemic stroke in humans is the middle cerebral artery, which affects the posterior 
frontal, lateral, and parietal lobes [103].  During a typical ischemic stroke (80% of all stroke cases), 
the human brain ages 3.6 years for each hour without treatment; this translates to loss of about 120 










dynamic; middle cerebral artery occlusion in mice results in rarefication (75% loss) of brain 
capillaries within the microinfarction core, while larger microvessels are unaffected [105].    
The induced occlusion of a single cortical penetrating arteriole in rats results in a cylindrical 
microinfarction core about 500 µm in diameter and extending about 1 mm into the cortex. Neuronal 
activity is completely diminished within 2 hours and conditions become severely hypoxic (PaO2 < 
10 mm Hg) in 6 hours [106].  However, occlusion of microvessels two or more branch points away 
from cortical penetrating arterioles (i.e. capillaries) does not lead to detectable microinfarctions, as 
flow in interconnected microvascular networks can reverse to compensate for the occlusion [106].  
Thus, the severity of ischemic stroke is heavily dependent on the location of the occlusion and 
presence of collateral circulation.  
The normal progression of ischemic stroke involves three phases.  In the acute phase (up to 48 
hours after onset), hypoxia leads to release of neurotransmitter glutamate which results in 
widespread excitotoxicity and subsequent neuronal injury [107].   When blood flow is restored to 
the infarction site either naturally or by intervention, reperfusion leads to further damage known as 
reperfusion injury.  Activated glial cells, damaged neurons, and other cells of the neurovascular 
unit release growth factors [108], matrix metalloproteinases [109], reactive oxygen species [110], 
glutamate [111], nitric oxide [112], and cytokines [113].  These compounds are implicated in 
diverse roles post-injury including angiogenesis, BBB breakdown, BM degradation, glial 
activation, and neurotoxicity [98, 114, 115].  Additionally, peripheral immune cells enter the brain 
with unique temporal dynamics, which in tandem with innate glial activation, generates a 
proinflammatory environment [116].  
The sub-acute phase of ischemic stroke, occurring between two days and six weeks, is associated 
with the initiation of repair.  In this phase, cerebrovascular plasticity is at its highest and many of 










plays a critical role in post-ischemic neurovascular remodeling.  However, the route and timing of 
VEGF administration following ischemic stroke modulate its therapeutic effects;  for example, 
systemic VEGF delivery during the acute phase promotes BBB disruption and worsens brain injury, 
while local modulation of VEGF or systemic delivery during the sub-acute phase may reduce 
ischemic damage [117, 118].  Following occlusion, BMECs begin proliferating and generating 
sprouts within 12 - 24 hours, leading to formation of new capillaries within three days after 
ischemic injury [119].  Additionally, brain pericytes play various roles in promoting microvessel 
stabilization and neuroprotection following stroke [120].  An important characteristic of the sub-
acute phase is the regenerative neurovascular niche, in which angiogenic blood vessels signal to 
neural progenitor cells to mediate neurogenesis.  This model is supported by the presence of newly 
formed neurons near remodeled vessels in the rodent striatum and cerebral cortex following stroke 
[121], most likely due to recruitment by BMECs that form a niche for neural stem cells [42].  During 
the chronic phase (after approximately 3 months following stroke), endogenous plasticity declines 
while vascular repair, angiogenesis, and behavioral improvement continue (although at a slower 
rate) [122]. 
1.7.2.Traumatic Brain Injury (TBI) 
TBI has diverse causes including blast-waves (i.e. improvised explosive devices), blunt trauma (i.e. 
contact sports) and penetration trauma (i.e. firearms).  Cerebrovascular changes during TBI occur 
in two distinct phases: primary and secondary.  During primary injury, direct biomechanical 
damage to cerebral tissue results in loss of cerebrovasculature architecture, CBF abnormalities, 
BBB disruption, and often fatal hemorrhaging and edema, while during secondary injury, cellular 
and molecular responses promote repair via angiogenesis, vasculogenesis, and neurogenesis [123, 
124].  The timescale and severity of responses in these phases is dependent on the injury modality, 










Traumatic brain injury results in rapid and significant decreases in microvascular density [11, 125].  
In an animal model of fluid percussion trauma, the cerebrovascular density of the ipsilateral 
cerebral hemisphere decreased by approximately 50% within 24 hours, while recovery was 
dependent on the severity of the injury and associated with establishment of a proangiogenic 
environment [125].  Other ultrastructural changes following TBI include BMEC swelling, vessel 
thinning, BM thickening, and pericyte degeneration [99].  In TBI patients, reduced CBF is observed 
within 12 hours after injury, while neurovascular uncoupling is thought to occur during the 
secondary phase [126].  Additionally, BBB disruption is widely observed following TBI and is 
associated with worse long-term outcomes, and may persist for years after injury contributing to 
risk of neurodegenerative disease [127, 128].  Angiogenesis and vasculogenesis are initiated during 
the secondary injury phase, resulting in increases in microvascular density over several weeks [99, 
125, 129].    Local hypoxia is thought to be the driver of neovascularization with HIF-1α and VEGF 
acting as critical molecular regulators [129]. 
1.7.3.Neurodegeneration  
Cerebrovascular structure, plasticity, and coupling are altered during neurodegenerative disease, 
beyond the impairments observed during normal aging [130, 131].  Whether cerebrovascular 
changes precede, follow, or occur concurrently with neurodegeneration is not yet fully understood, 
however, accumulating evidence suggests that cerebrovascular changes can occur prior to the 
presentation of symptoms and promote neurodegeneration [132-141]. 
Neurodegenerative disease is characterized by progressive loss of functional neurons and 
compromised human brain function.  Age is the greatest risk factor for neurodegenerative disease 
[142].  Neurodegeneration and normal brain aging share common pathologic origins including 
oxidative stress, mitochondrial dysfunction, and proteotoxicity [142, 143].  However, 










and genetic), histopathological hallmarks (neuronal loss in specific brain regions and formation of 
protein aggregates), and clinical manifestations.  Despite the pathogenic differences, several themes 
connect cerebrovascular changes during neurodegeneration: (1) BBB dysfunction [6, 80, 130], (2) 
cerebral hypoperfusion and glucose hypometabolism [144], and (3) overexpression (AD, PD, HD) 
or underexpression (ALS) of VEGF (Table 1-1) [37]. 
1.7.3.1.Alzheimer’s disease (AD) 
Cerebrovascular changes associated with Alzheimer’s disease include vascular degeneration, 
altered angiogenesis, reduced CBF, increased BBB permeability, and neurovascular uncoupling 
[130, 133]. The amyloid hypothesis states that the formation of amyloid-β (predominantly the Aβ-
42 isoform) within the brain parenchyma induces gain of toxic function and neurodegeneration.  
However, AD is also closely associated with cerebral amyloid angiopathy (CAA) which is 
characterized by perivascular accumulation of predominantly the Aβ-40 isoform in the BM of 
leptomeningeal and cortical vessels of the cerebrum and cerebellum [145].  The epidemiological 
link between cerebrovascular risk factors and AD pathogenesis is well established and has been 
reviewed elsewhere [146]. 
Postmortem analysis of AD brain reveals capillary loss, as well as atrophied BMECs and pericytes, 
swollen astrocytic end-feet, hypercontractile SMCs, BM thickening, and BM deposits [18, 147].  
In severe CAA, additional pathologies include SMC loss, duplicated lumens, fibrinoid necrosis, 
and hyaline degeneration [145].  Despite capillary loss, AD is associated with increased 
concentrations of VEGF [148, 149].  In post-mortem human AD tissue, an increase in the number 
of angiogenic vessels (integrin αvβ3 expression) was correlated with several AD pathologies 
including neurofibrillary tangles and Aβ load [150].  Transgenic AD animal models corroborate 
these findings; in aged Tg2576 mice, disruption of tight junctions was linked to increased 










disruption in early-stage AD, while microvascular degeneration occurs in last-stage AD [151].  
However, the effects of amyloid-β on brain angiogenesis remain convoluted as amyloid-β has been 
reported to both promote and suppress angiogenesis both in vitro and in vivo [152, 153]. 
Reduced CBF, increased BBB permeability, and reduced glucose metabolism are found to precede 
AD neurodegeneration in animal models and human studies.[50]  Reduced CBF is found in patients 
at high risk of developing AD (APOE ε4 allele) and patients with mild cognitive impairment [154, 
155].  These reductions persist during AD progression and appear to correlate with the degree of 
cognitive decline and AD pathology [18].  Recently, neutrophil adhesion in brain capillaries has 
been shown to reduce cortical blood flow in AD mouse models [156].  Additionally, BBB 
permeability increases before plaque formation in an AD mouse model, while MRI studies indicate 
that increased BBB permeability of mild cognitive impairment patients correlates with AD 
cognitive decline [132, 134].  PET imaging studies find reduced glucose metabolism in patients at 
high risk of AD, which precedes brain atrophy [130, 157].  CBF, metabolic rate, and BBB 
permeability changes contribute to ischemic/hypoxic damage of the neurovascular unit and initiate 
and/or exacerbate AD pathology [50, 130].  
AD patients, APOE ε4 allele carriers, and transgenic AD mice exhibit impaired neurovascular 
coupling responses, while therapies that rescue neurovascular coupling are associated with 
cognitive improvements [93, 135, 158].  AD-associated changes in vascular reactivity factors (i.e. 
eNOS and endothelin-1) may underlie neurovascular uncoupling and chronic hypoperfusion [159].  
Interestingly, partial eNOS deficiency in mice results in CAA-like pathologies and stroke in brain 
regions associated with hypoperfusion in preclinical AD patients [160]. 
1.7.3.2.Parkinson’s disease (PD) 
Cerebrovascular changes associated with Parkinson’s disease include both vascular degeneration 










the substantia nigra in the brainstem [161].  Additionally, Lewy bodies, aggregates of 
predominately α-synuclein, form in the cytoplasm of specific neurons in widespread brain regions.  
Impairment of α-synuclein degradation during aging may contribute to dopaminergic neuronal loss 
and downstream motor deficient (bradykinesia) observed in PD patients [143]. 
PD-associated vascular degeneration resembles that of AD; morphological changes include BMEC 
degeneration and decreases in microvascular density [147, 162].  However, other studies find 
increased angiogenic vessels (integrin αvβ3 expression) in PD-associated brain regions, without 
overt changes in microvascular density [163].  Thus, it is possible that a proangiogenic environment 
is established in PD patients, as evidenced by heighted angiogenic biomarkers [164].  Integrin αvβ3 
expression is co-localized with BBB leakage in animal models of PD (6-hydroxydopamine mouse 
model) while the striatum in postmortem PD sections demonstrates signs of BBB disruption, 
suggesting that angiogenesis disrupts the BBB, thereby contributing to vascular degradation in late-
stage disease [165, 166].  Additionally, hypoperfusion of specific brain regions of PD patients is 
correlated with motor dysfunction [167]. 
Elevated microvascular plasticity in PD patients treated with deep brain stimulation (DBS) has 
recently been reported [168].  Reductions in microvascular density, endothelial tight junction 
protein expression, and endothelial VEGF expression were found in PD patients compared to age-
matched controls.  However, in PD patients treated with subthalamic nucleus DBS, these 
cerebrovascular changes were reversed.  Increased neural activity promoted by DBS rapidly 
modulates production of neurotrophic and angiogenic factor such as VEGF and BDNF [169]. 
1.7.3.3.Huntington’s disease (HD)  
Huntington’s disease is associated with cerebrovascular alterations including increased 
microvascular density, BBB disruption, and altered cerebral hemodynamics.  HD is caused by 











Table 1-1. Changes in cerebrovascular structure, plasticity, and coupling occur in AD, PD, HD, and ALS. 
 
For each disease neuropathological hallmarks as well as cerebrovascular changes are summarized.   Across the four most common NDs there are 
reported reductions in cerebral blood flow (CBF) and increases in blood-brain barrier (BBB) permeability.   Overexpression (AD, PD, HD) or 
underexpression (ALS) of vascular endothelial growth factor which drives brain angiogenesis may underlie ultrastructural changes.  While vascular 
degeneration is widely reported in AD and PD (characterized by decreased microvessel density), elevated microvessel density may occur in early-





Neuropathological hallmarks Microvascular ultrastructure Angiogenesis Hemodynamics NVU dysfunction 
Alzheimer’s 
disease (AD) Extracellular amyloid-β plaques, intracellular tau tangles, loss of 
synapses and neurons 
(predominately cerebral cortex) 
Cerebral amyloid angiopathy 
[145] 
vascular degeneration [18, 147] 
↓ microvascular density [36]   
↑ angiogenic vessels 
[150, 151] 
↑ VEGF [148, 149] 












aggregates and loss of 
dopaminergic neurons (substantia 
nigra, other regions) 
vascular degeneration,  
↓ microvascular density [147, 
162] 
 
↑ angiogenic vessels and 





disease (HD)  
 Intracellular mutant huntingtin (mHTT) aggregates and loss of 
neurons (striatum, cortex, 
hippocampus, others) 
↑ microvascular density [171, 
172] 
↑ angiogenic potential of 
HD hiPSC-derived 
BMECs [137] 
↑ astrocytic VEGF [173] 
















SOD-1 or TDP-43 aggregates and 
loss of motor neurons (cortex, 
brainstem, spinal cord) 













huntingtin (mHTT) protein, produced by neurons and astrocytes, aggregates within the brain 
parenchyma, BM of microvessels, and cells of the NVU [171].  Loss-of-function of normal HTT 
and gain-of-function of mHTT contributes to progressive loss of neurons in the striatum, cortex, 
and hippocampus, among other regions, accompanied by declines in cognitive and motor functions 
[170]. 
In HD patients and mouse models of HD, microvascular density is increased up to two-fold 
compared to age-matched healthy controls [171, 172].  BBB disruption has been observed in HD 
mouse models, brain imaging of mild-to-late stage HD patients, and postmortem studies of HD 
tissue [171].  Changes in tight junction expression that underlie increased BBB permeability were 
recently found to precede disease presentation in a mouse model (R6/2) [136]. 
Astrocytes have been implicated as a mediator of microvascular changes; increased astrocytic 
VEGF in a HD mouse model (R6/2) promoted angiogenesis and loss of pericytes contributing to 
abnormal cerebral autoregulation [173].  Recent work suggests that BMECs of HD patients are 
autonomously dysfunctional; human induced pluripotent stem cells (hiPSCs) derived into BMECs 
from HD patients exhibit elevated angiogenic potential and deficient BBB properties compared to 
healthy cell lines [137].  Additionally, reductions in cortical CBF and impaired neurometabolic 
coupling have been reported in early stage HD patients and the R6/2 mouse model, respectively 
[138, 139]. 
1.7.3.4.Amyotrophic Lateral Sclerosis (ALS) 
During amyotrophic lateral sclerosis, progressive degeneration of motor neurons in the cortex, 
brainstem, and spinal cord lead to loss of voluntary muscle control and generalized paralysis.  Many 
molecular mechanisms have been implicated in ALS pathogenesis, including failure of proteostatis, 
mutations of RNA-binding proteins, axonal transport dysfunction, cytoskeletal disarrangement, and 










dysfunction, including BBB breakdown, has been reviewed elsewhere [174].  In SOD1 mutant 
mouse models, disruption of the blood-spinal cord barrier was observed prior to the development 
of symptoms of the disease and prior to an inflammatory response [140], suggesting that vascular 
changes can precede symptomatic disease. 
Genetic alterations in expression of hypoxia-inducible genes are heavily implicated in ALS 
pathogenesis.  Mice with reduced VEGF levels develop progressive motor neuron degeneration 
resembling human ALS, and reduced VEGF accelerates motor neuron degeneration in familial ALS 
mouse models [175, 176].  Humans with genetic variations of the VEGF promoter that confer low 
levels of circulating VEGF are at heightened risk to develop ALS [176].  Interestingly, early ALS 
patients demonstrated reduced CSF VEGF levels independent of VEGF promoter polymorphisms 
[141].  Insufficient VEGF likely contributes to ALS progression by both depriving neurons of 
neurotrophic signals and by contributing to BBB dysfunction and hypoperfusion/ischemia [37]. 
1.8.Summary 
During normal brain function, local changes in neural activity are accompanied by local 
dilation/contraction of microvessels to meet current metabolic demands.  Under these conditions 
the cerebrovascular architecture is generally thought to be fixed and, at the cellular level, the 
turnover of BMECs is negligible.  However, subtraction and pruning of redundant loops suggest 
that the cerebrovasculature is not completely static during homeostasis.  During development, 
neuronal and glial interactions drive additive changes in the cerebrovasculature, while the loss of 
neurons associated with aging is accompanied by heterogeneous subtractive changes.  Injury and 
disease can also result in subtractive loss and induce subsequent repair processes.  Sustained 
changes in the global brain microenvironment due to sensory deprivation or hypoxia, can also lead 










common factor in all additive changes in the cerebrovasculature is VEGF, a protein involved in 
vasculogenesis and angiogenesis, and expressed and recognized by BMECs, glial cells, and neurons 
Model systems to study cerebrovascular plasticity are continually advancing.  Multiphoton and 
intravital microscopy support studies of cerebrovascular plasticity in living animal models.[32-35]  In 
humans, neuroimaging modalities (i.e. fMRI) provide real-time metrics of cerebrovascular 
function, while postmortem histological analyses provide information on cerebrovascular structure.  
There remains a need for techniques to study human cerebrovascular plasticity with high temporal 
and spatial resolution.  In vitro models of cerebrovascular plasticity may satisfy this need.  
However, current models fail to recapitulate in vivo structure, function or plasticity.  For example, 
while transwell assays (comprised of BMECs cultured on a permeable membrane) can achieve 
physiological permeability, it does not mimic physiological hierarchy or geometry [26].  Without 
three-dimensional structure, models of cerebrovascular plasticity will fail as they cannot 
recapitulate additive or subtractive changes of capillaries.  Recent advances in stem cell technology, 
microfluidics, and tissue engineering have led to three-dimensional cerebrovascular models with 
increasing complexity [180, 181].  However, their ability to achieve characteristic stability of 
cerebrovascular architecture during homeostasis and plasticity during perturbation has yet to be 
shown.  Development of stable three-dimensional models of the cerebrovasculature will support 
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2.1.Introduction 
The blood-brain barrier (BBB) maintains tight control of the brain microenvironment by regulating 
fluctuations in chemistry, transport of immune cells, and entry of pathogens and toxins [182-184].   
The brain microvascular endothelial cells (BMECs) that form the lumen of the cerebrovasculature 
are highly specialized, expressing tight junctions which effectively block paracellular transport, 
and an array of transporters and efflux pumps which regulate transcellular transport.  Additionally, 
BMECs display low turnover and motility to maintain a quiescent state in the healthy 
cerebrovasculature. Differences in the cerebrovasculature between humans and rodents mean that 
animal models do not always recapitulate human disease [185].  Therefore, in vitro models can 










contribute to elucidating disease mechanisms and developing new strategies for drug and gene 
delivery to the brain. However, for widespread adoption, these in vitro models must achieve 
physiological barrier function and endothelial cell behavior. 
Advances in tissue engineering have led to the development of a new generation of perfusable 
three-dimensional (3D) models of the BBB [186-189].  However, recapitulating physiological tight 
junction formation and barrier function has been particularly challenging, largely due to the fact 
that primary and immortalized human and animal brain microvascular endothelial cells exhibit 
transendothelial electrical resistance (TEER) values well below the range thought to be 
physiological (1,500 – 8,000 Ω cm2) [190-193].  To overcome this limitation, many existing BBB 
models incorporate supporting cell types of the neurovascular unit (i.e. astrocytes and pericytes) 
which improve barrier function, but still do not achieve physiological TEER or permeability.  Brain 
microvascular endothelial cells differentiated from human induced pluripotent stem cells 
(dhBMECs) display many of the hallmarks of the BBB in two-dimensional (2D) transwell assays 
including physiological TEER, permeability and efflux behavior [194-197].  Interestingly, BBB 
phenotype is achieved without supporting cell types.  In previous work we have reported on the 
role of matrix composition and stiffness on the adhesion and barrier formation of dhBMECs 
relevant to tissue engineering of 3D microvessel models [198]. 
Here, we report on characterization of an in vitro model of a brain post-capillary venule (PCV).  
PCVs are characterized by diameters of around 100 µm, a relatively thick basement membrane, a 
perivascular space with limited supporting cells, and a wall shear stress of 1 - 4 dyne cm-2 [199-
202].  PCVs are the site for immune surveillance and preferential extravasation of leukocytes, 
tumor cells, parasites and viruses [28, 203-208].  We report on the structure (i.e. endothelial cell 
behavior) and function (i.e. permeability) of the human iPSC-derived PCV model, in comparison 










(HUVECs).   We show that the dhBMEC microvessels recapitulate key aspects of the human BBB 
including physiologically low solute permeability, cell turnover, and cell motility.  Compared to 
self-organizing approaches recently developed for BBB modeling, which mimic angiogenesis and 
vasculogenesis, our microvessels are functional after only two days of culture and without the 
complexities of co-culture with astrocytes or pericytes [180, 209].  In addition, endothelial cells are 
all in contact with extracellular matrix and hence the microvessel lumen is able to constrict or dilate 
in response to transmural pressure or other perturbations.  We provide proof-of-principle examples 
of how a physiological brain PCV model can be used to study biologically- and clinically-relevant 
processes, including patient-specific models of neurodegenerative disease, efflux inhibition, 
hyperosmolar opening of the BBB, and activation by inflammatory cytokines.  
2.2.Materials and Methods 
2.2.1.Cell culture 
Human brain microvascular endothelial cells (dhBMECs) were differentiated from induced 
pluripotent stem cells (iPSCs) as previously reported [196].  Briefly, iPSCs were singularized using 
StemPro accutase (Thermo Fisher) and seeded at 15,000 cells cm-2 on Matrigel-treated six-well 
plates (Corning).  Cell lines used:  BC1 and iPS12 [210], KW01, and AD6 [211].  The BC1 and 
iPS12 lines were derived from healthy individuals.  The AD6 line was derived from skin fibroblasts 
(Coriell Institute) of a 56-year-old male with Alzheimer’s disease harboring the familial AD PSEN1 
mutation A246E [211].  The KW01 line was derived from a 73-year-old male with multiple 
sclerosis.  All iPSC lines were used between passage 30 - 70.  Cells were cultured in TeSR-E8 
media (Stem Cell Technologies) for three days to approximately 40% confluence, with 10 µM 
ROCK inhibitor Y27632 (ATCC) supplemented for the first 24 hours.  The differentiation was then 
initiated in unconditioned media without bFGF (UM/F-): DMEM/F12 (Life Technologies) 










acids (Life Technologies), 0.5% GlutaMAX (Life Technologies) and 0.836 µM beta-
mercaptoethanol (Life Technologies).  After six days of UM/F- culture, cells were cultured for two 
days in BBB induction media: human endothelial cell serum-free media (Life Technologies) 
supplemented with 1% human platelet poor derived serum (Sigma), 2 ng mL-1 bFGF (R&D 
Systems), and 10 µM all-trans retinoic acid (Sigma).  Media was changed every 24 hours.  After a 
total of 11 days in culture, cells were detached using accutase and sub-cultured onto plates coated 
overnight with 50 µg mL-1 human placental collagen IV (Sigma) and 25 µg mL-1 fibronectin from 
human plasma (Sigma).  Sub-cultures were conducted at a 1:1 surface area ratio (one well of 
differentiated cells sub-cultured onto one well of six-well plate) and in BBB induction media 
supplemented with 10 µM ROCK inhibitor Y27632.  After one hour, cell monolayers were washed 
three times with phosphate buffered saline (PBS; Thermo Fisher), detached with accutase, and 
seeded into microvessels once resuspended in BBB induction media supplemented with 10 µM 
ROCK inhibitor Y27632 to 50 million cells mL-1. 
Human umbilical vein endothelial cells (HUVECs) were used up to passage six.  HUVECs were 
grown in MCDB 131 (Caisson) supplemented with 10% fetal bovine serum (Sigma), 1% pen-strep-
glut (Thermo Fisher), 1 µg mL-1 hydrocortisone (Sigma), 10 µg mL-1 heparin (Sigma), 25 µg mL-1 
endothelial cell growth supplement (Thermo Fisher), 0.2 mM ascorbic acid 2-phosphate (Sigma), 
and 80 µM dibutyryl cyclic-adenosine monophosphate (db-cAMP; Sigma).  TrypLE Express (Life 
Technologies) was used to detach cells for routine passing and seeding of microvessels.  HUVECs 
were resuspended to 10 million cells mL-1 in media for seeding microvessels. 
2.2.2.Microvessel fabrication, perfusion, and maintenance  
To fabricate microvessels, 1 cm (length) x 1.75 mm (width) x 1 mm (height) channels were 
patterned in Sylgard 184 polydimethylsiloxane (PDMS; Dow Corning) using an aluminum mold 










trimethoxysilane (Sigma) to reduce formation of bubbles at the PDMS-collagen interface.  
Neutralized 7 mg mL-1 rat tail type I collagen (Corning) was gelled around a 150 μm diameter 
super-elastic nitinol wire (Malin Co.) for 30 minutes at 37°C.  To prevent delamination of the gel, 
2% agarose was added to both sides of the collagen gel.  Following removal of the template wires, 
the bare channels were cross-linked with 20 mM genipin (Wako Biosciences) for two hours.  
Residual genipin was removed by perfusing channels under high flow (~0.5 mL h-1) with PBS for 
at least 12 hours.  Lastly, channels were coated overnight with 50 µg mL-1 collagen IV and 25 µg 
mL-1 fibronectin in either HUVEC or dhBMEC microvessel media (composition outlined below).  
Derived hBMEC microvessels were seeded and perfused using brain microvessel media: 
endothelial cell serum-free media (Life Technologies) supplemented with 1% human platelet poor 
derived serum (Sigma), 1% penicillin-streptomycin (Life Technologies), 400 µM db-cAMP, 20 
µM phosphodiesterase inhibitor Ro-20-1724 (Calbiochem), and 3% 70-kDa dextran (Sigma).  Both 
retinoic acid and bFGF (present during the last two days of the differentiation) were removed from 
the microvessel media.  Additionally, 10 µM ROCK inhibitor Y27632 was supplemented during 
the first 24 hours of microvessel perfusion to increase adhesion [198, 212]. 
HUVEC microvessels were seeded and perfused using HUVEC microvessel media: HUVEC cell 
culture media supplemented with 400 µM db-cAMP, 20 µM Ro-20-1724, and 3% 70-kDa dextran.  
These additions have previously been shown to promote barrier function and long-term stability of 
in vitro microvessels [213-215].   Confluent HUVEC microvessels do not form using brain 
microvessel media (data not shown). 
Microvessel shear stress was estimated by Poiseuille’s equation: τ = µQ / 2πd3 where µ is the fluid 
dynamic viscosity (~1.4 cP for media supplemented with 3% dextran), Q is the volumetric flow 
rate, and d is the microvessel diameter.  The volumetric flow rate was measured daily as the increase 










maintained with a reservoir height difference (Δh) of 5 cm, corresponding to a volumetric flow rate 
of ~ 0.5 mL h-1.   
 
Figure 2-1. Fabrication, perfusion, and maintenance of human iPSC-derived blood-brain 
barrier microvessels.  (A,B) Schematic illustrations of the side- and end-view of 150 µm diameter 
microvessel fabrication.  (C) Phase contrast images of sequential microvessel fabrication steps.  (D) 
PDMS-based microfluidic chip.  (E) Perfusion system comprised of tubing connecting inlet and 
outlet ports to an upper and lower media reservoir (∆h = 5 cm).  (F) Shear stress for BC1 dhBMEC 
and HUVEC microvessels over six days.  (G) Phase contrast images of brain-specific microvessels 
constructed from various iPSC lines including BC1, iPS12, KW01, and AD6 on day two after 
seeding.  (H,I) Fluorescence images of blood-brain barrier (BBB) markers in BC1 dhBMEC 
microvessels on day 2:  zona occluden-1 (ZO1), occludin, claudin-5, glucose transporter-1 
(GLUT1), and P-glycoprotein (P-gp).  Images shown are a 0.4 µm confocal z-slice of the bottom 
microvessel pole, or a cross-section of the microvessel.  Nuclei visualized with DAPI (blue). 
 
2.2.3.Live-cell imaging 
The strategy for live-cell imaging of dhBMEC and HUVEC microvessels is summarized in Figure 
2-2.  Microvessels were imaged using an inverted microscope (Nikon Eclipse Ti-E) maintained at 










(Excelitas Technologies).  A 10x objective (Nikon) was used for all epifluorescence and phase-
contrast images.  Imaging of microvessels was conducted on days two, four and six after seeding. 
Permeability was simultaneously measured for three different molecular weight solutes introduced 
into the upper media reservoir at a final concentration of 200 µM Lucifer yellow (CH dilithium 
salt; LY) (Sigma), 5 µM Rhodamine 123 (R123) (Thermo Fisher), and 2 µM Alexa Flour-647-
conjugated 10 kDa dextran (Thermo Fisher).  A NIS Elements (Nikon) imaging protocol was 
initiated to acquire both phase contrast and fluorescence images every two minutes for two hours 
(61 total frames).  At every time point six images were collected: (1) a phase contrast image of the 
top of the microvessel (located and maintained by autofocus), (2-5) phase contrast and fluorescence 
images of the microvessel midplane, and (6) a phase contrast image of the bottom of the 
microvessel.  To independently excite and collect the emission from each fluorophore, three filter 
cubes were used: Chroma 39008 for Lucifer yellow (20 ms exposure), Chroma 49003 for 
Rhodamine 123 (50 ms exposure), and Chroma 41008 for Alexa Fluor-647-conjugated dextran 
(200 ms exposure).  The total image area was 8.18 mm x 0.67 mm, corresponding to ten adjacent 
frames using a 10x objective.   
2.2.4.Permeability 
Large images were cropped to an area of 1 mm x 0.67 mm (corresponding to a single 10x 
magnification frame); a central region of the large image was chosen to minimize contributions of 
interstitial flow of solutes from the inlet and outlet.  Intensity profiles were obtained using ImageJ 
(NIH).  The apparent permeability (cm s-1) is calculated as P = (d/4)(1/ΔI)(dI/dt), where d is the 
vessel diameter, ΔI is the initial increase in fluorescence intensity upon luminal filling, and (dI/dt)0 
is the rate of increase in fluorescence intensity as solute exits into the gel [216, 217].  Over the 
course of two hour imaging experiments there are four phases: (i) before the solute reaches the 











Figure 2-2. Live-cell imaging of human iPSC-derived blood-brain barrier microvessels.(A) 
representative phase contrast images of a BC1-derived brain microvessel on days two, four and six 
under a wall shear stress of about 4 dyne cm-2.  (B) Phase contrast and fluorescence images of 
perfusion with Lucifer yellow, Rhodamine 123, and 10 kDa dextran at the microvessel midplane.  
(C,D) Phase contrast images at the top and bottom planes, respectively.  (E) Representative 
fluorescence intensity for Lucifer yellow for a region of interest comprising both the microvessel 
and surrounding matrix:  (i) Prior to perfusion of the dye.  (ii)  luminal filling where ∆I represents 
the increase in fluorescence intensity.  (iii) Penetration of the dye into the surrounding matrix results 











(iii) while the solute permeates into the ECM, and (iv) when solute continues to permeate into ECM 
and where interstitial flow of solutes interferes with quantification.  After luminal filling, the 
intensity increase (dI/dt) was calculated over twenty minutes.  For Rhodamine 123, to eliminate the 
contributions of intracellular accumulation, the permeability was also calculated by considering 
only the rate of increase in fluorescence intensity in the ECM; unless otherwise noted this value is 
reported for Rhodamine 123 permeability [218].  The detection limit for permeability of Alexa 
Flour-647-conjugated 10 kDa dextran (≤ 1 x 10-7 cm s-1) was limited by photobleaching of the 
genipin cross-linked collagen gel.  Some brain microvessels displayed macroscopic breakdown 
past day four of perfusion (~30% of devices); these microvessels were not considered in time course 
permeability analysis.  Monolayer breakdown is not observed on transwells on this timescale, 
suggesting that cell-ECM interactions may contribute to model instability.  
For studies of efflux inhibition, 2 µM tariquidar (Sigma) was supplemented in brain microvessel 
media at 36 hours after cell seeding.  Day two permeability and cell behavior analysis was 
conducted as outlined above after 12 hours of tariquidar exposure.  To determine the relative 
contributions of sequestration and transport of solutes we calculated permeability considering an 
ROI excluding the lumen and intracellular compartment, and an ROI of the entire image frame.   
2.2.5.Cell behavior 
To assess endothelial cell behavior in microvessels, we quantified cell area (µm2), proliferation rate 
(% h-1), the rate of cell loss (% h-1), turnover rate (% h-1), root mean square (RMS) displacement 
(µm), path length (µm), number of nearest neighbors, and frequency of nearest neighbor change (h-
1) of BC1 dhBMEC microvessels.  Details of the protocols have been published previously [219-
222]. Phase contrast image sequences from the top and bottom planes were independently analyzed 
at each time point using ImageJ.  Analysis was performed in a region of interest (ROI) ~100 µm 










mm).  This width was selected to minimize foreshortening of the lumen due to microvessel 
curvature.  Any regions along the microvessel length that were significantly out of focus were 
excluded from the ROI. The total number of cells was quantified by identifying individual cell 
nuclei within the ROI.  Cell area was calculated by dividing the total area of the region of interest 
by the number of cell nuclei.  From analysis of fluorescence images following staining with DAPI 
and f-actin, we independently verified that there was less than 10% error between the 
measurements. 
The rates of cell proliferation and cell loss were quantified through identification of cell division 
and loss events within the ROI. Proliferation events are easily identified in time-lapse phase 
contrast images from cell compression, alignment of chromosomes, and the formation of daughter 
cells. Cell loss events were readily identifiable through cell compression, lysing of cell contents, 
and removal of the cell from the monolayer. Events were monitored over the duration of time-lapse 
imaging and labeled with their location and time at which they occurred. The rates of cell 
proliferation and cell loss (% h-1) were determined by summing the number of events in the imaging 
window and dividing by the total number of cells within the ROI (n = 16753 dHBMECs and n = 
14042 HUVEC cells sampled for analysis). 
To assess cell motility, we tracked the location of the cell nuclei within the region of interest over 
two hours of imaging.  Root mean square (RMS) displacement (µm) is a measure of how far the 
cell moved from its original position, while path length (µm) is a measure of the total distance cells 
traverse.  At least ten cells were randomly selected over the length of the microvessel per timepoint 
for motility analysis (n = 291 dHBMECs and n = 171 HUVEC cells sampled for analysis).  Using 
ImageJ, a point was placed on the centroid of the cell nucleus at each frame, resulting in an array 
of (x, y) coordinate pairs for each time point within the time-lapse sequence. A reference point 










Additionally, from phase contrast images we quantified the number of cell neighbors for each cell, 
as well as the frequency of change in cell neighbors.  Cells are considered neighbors when they 
share a border, and the number of cell neighbors can change due to proliferation, cell loss, cell 
movement, or due to redistribution of tight junctions.  From analysis of fluorescence images stained 
for f-actin, we verified that there was less than 10% error in the number of cell neighbors between 
the two methods. 
2.2.6.Immunocytochemistry 
On day two after seeding, microvessels were washed with PBS for 5 minutes, fixed with 3.7% 
paraformaldehyde (Sigma) for 15 minutes, permeabilized with 0.1% Triton X-100 (Sigma) for 15 
minutes, and blocked with 1% donkey serum (Sigma) overnight at 4°C.  Microvessels were 
incubated for 6 hours at 4°C with primary antibodies and for 20 minutes at room temperature with 
Alexa Flour-647 and Alexa Flour-488 secondary antibodies (Life Technologies) (Table 2-1).  To 
localize nuclei or f-actin, 1:500 DAPI solution (Thermo Scientific) and 1:50 AlexaFluor647 
phalloidin (Invitrogen) were added, respectively.  Confocal z-stacks were obtained on a swept field 
confocal microscope system (Prairie Technologies) with illumination provided by MLC 400 
monolithic laser combiner (Keysight Technologies).  To fully reconstruct microvessels, 
approximately four hundred 0.4 µm slices were acquired using a 40x objective (Nikon). 
Table 2-1.  Antibodies used in this study. 
Antibody Vendor Species Cat. No Dilution 
ZO-1 Invitrogen Rabbit 402200 1:200 
GLUT1 Abcam Rabbit 115730 1:100 
P-gp Sigma Mouse P7965 1:50 
Claudin-5 Invitrogen Mouse 35-2500 1:50 
Occludin Invitrogen Mouse 33-1500 1:50 
Laminin α-4 R&D Mouse MAB7340 25 µg/mL 
VCAM-1 Abcam Rabbit 134047 1:50 










2.2.7.Hyperosmolar microvessel opening 
An intra-arterial osmotic procedure is used in neuro-oncology for transient opening of the blood-
brain barrier to facilitate drug delivery to tumors.  To model this procedure, 250 mg mL-1 d-
mannitol (Sigma) in brain microvessel media was introduced into the upper media reservoir for 
five minutes on day two following seeding.  Mannitol was then replaced with 200 µM Lucifer 
yellow and 2 µM Alexa Fluor647-conjugated 10 kDa dextran in brain vessel media.  Live-cell 
imaging and analysis was conducted as previously outlined.  Additionally, structural changes 
observed after exposure to mannitol (i.e. intracellular vacuoles) were counted in ImageJ using time-
lapse phase contrast images of microvessel poles cropped to an area of twenty cells; vacuole count 
was normalized to the number of cells.     
2.2.8.Leukocyte adhesion 
To determine the effect of tumor necrosis factor alpha (TNFα) activation on permeability and 
leukocyte adhesion, two media conditions were used.  In control experiments, microvessels were 
perfused with endothelial cell serum-free media supplemented with 1% human platelet poor 
derived serum and 1% penicillin-streptomycin.  To model inflammatory conditions, microvessels 
were perfused with control media supplemented with 10 ng mL-1 TNFα (Thermo Fisher) for 12 
hours. On day two, either permeability was tested (as previously summarized) or leukocyte 
adhesion was tested.  For both conditions, microvessels were maintained at ~1 dyn cm-2 shear stress 
using fluid reservoirs directly connected to the inlet and outlets.   Human peripheral blood 
mononuclear cells (PBMCs, StemCell Technologies), predominately comprised on lymphocytes 
and monocytes, were used for adhesion studies.  PBMCs were freshly thawed and resuspended in 
RPMI-1640 media supplemented with 10% FBS and 1% penicillin-streptomycin before use. Prior 
to the microvessel experiments, PBMCs were labeled by incubating with 5 µM Calcein AM 










concentration of 106 cells mL-1 and allowed to flow through the microvessel for a duration of 30 
minutes.  After five minutes of washout, fluorescent images of the microvessel poles and midplane 
were taken to quantify adherent cells, which were normalized to microvessel length.   VCAM-1 
and ICAM-1 expression was visualized using immunocytochemistry as previously described.    
2.2.9.Statistical Analysis 
All statistical analysis was performed using Prism ver. 6 (GraphPad).  Experimental metrics (i.e. 
permeabilities, shear stresses, turnover) are presented as means ± standard error of the mean (SEM).  
The principle statistical tests used were a student’s unpaired t-test (two-tailed with unequal 
variance) for comparison of two groups and an analysis of variance (ANOVA) for comparison of 
three or more groups.  Reported p values were multiplicity adjusted using a Tukey test.  A one 
sample t-test was used to determine if sample mean was statistically different from zero.  
Differences were considered statistically significant for p < 0.05, with the following thresholds: * 
p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  
2.3.Results 
2.3.1.Human iPSC-derived brain microvessels express blood-brain barrier markers and 
maintain stable perfusion over at least six days 
Using a templating method we have engineered a functional model of a human brain post-capillary 
venule (PCV) with stem-cell derived brain microvascular endothelial cells (dhBMECs) (Figure 
2-1).  In previous work we screened matrix composition, stiffness, and soluble factors to promote 
adhesion and spreading of dhBMECs in tissue-engineered microvessels [198].  Here, dhBMECs 
were seeded into a cylindrical 150 μm diameter channel in 7 mg mL-1 type I collagen gels, cross-
linked with 20 mM genipin and coated with fibronectin and type IV collagen.  Additionally, ROCK 
inhibitor Y27632 was added to promote cell survival over the first 24 hours of culture.  










volumetric flow rates the wall shear stress was determined to be around 4 dyne cm-2, typical of 
post-capillary venules.  This approach enabled the formation of microvessels with dhBMECs 
derived from multiple iPSC lines.  dhBMEC microvessels formed from the BC1 iPSC line 
displayed proper localization of the tight junction proteins zonula occludens-1 (ZO-1), claudin-5 
(CLDN-5) and occludin (OCLN), and blanket expression of glucose transporter 1 (GLUT1) and 
the p-glycoprotein (P-gp) efflux pump.   
2.3.2.Brain microvessels display physiological barrier function  
The permeability of dhBMEC and HUVEC microvessels was determined on days two, four and six 
from simultaneous measurement of the transport of three fluorescent probes: Lucifer yellow (LY), 
Rhodamine 123 (R123), and Alexa Flour-647-conjugated 10 kDa dextran (Figure 2-2).  LY is a 
small (444.3 Da) negatively charged water-soluble dye used in vivo and in vitro to assess BBB 
integrity.  Rhodamine 123 is a small molecule (380.8 Da) that is a substrate for efflux pumps, 
including p-glycoprotein.  10 kDa dextran conjugated to Alexa Fluor-647 is a large molecular-
weight polysaccharide used as a marker of vascular permeability.  The global permeability was 
obtained from the increase in intensity of the imaging ROI during solute perfusion. 
Representative phase / fluorescence overlays of microvessels during permeability measurements 
show perfusion of the solute in the lumen and transport into the ECM (Figure 2-3).  BC1 dhBMEC 
microvessels displayed stable permeability over six days.  The permeability of Lucifer yellow was 
2.50 ± 0.46 x 10-7 cm s-1 on day two and did not increase on days four and six (p > 0.05), with an 
average value of 2.84 ± 0.41 x 10-7 cm s-1 across all time points.  The permeability of Rhodamine 
123 in dhBMEC microvessels was 6.61 ± 0.26 x 10-7 cm s-1 on day two when considering the entire 
ROI for analysis; however, if the microvessel lumen and cells are excluded it was 1.32 ± 0.16 x 10-
7 cm s-1.  This dramatic difference, which was not observed with other solutes (data not shown), 











Figure 2-3. Permeability of human iPSC-derived blood-brain barrier microvessels.   
Representative phase / fluorescence overlays of Lucifer yellow, Rhodamine 123, and 10kDa 
dextran perfusion in (A) BC1 dhBMEC microvessels, and (B) HUVEC microvessels. t = 0 min 
represents the frame prior to initiation of luminal filling.  Luminal filling occurred on average over 
20 minutes for Lucifer yellow and Rhodamine 123, and 30 minutes for 10 kDa dextran.  The rate 
of fluorescence change was determined over subsequent 20 minutes after luminal filling.  (C-E) 
Permeability of Lucifer yellow, Rhodamine 123, and 10 kDa dextran in HUVEC and BC1 
dhBMEC microvessels.  (F-H) Permeability of Lucifer yellow, Rhodamine 123, and 10kDa 
dextran, in dhBMEC microvessels derived from multiple iPS cell lines (BC1, iPS12, KW01, AD6) 
on day two following seeding.  Experiments were performed on at least three microvessels for each 











remained stable on day four and six (p > 0.05).  The permeability of 10 kDa dextran conjugated to 
Alexa Flour-647 in dhBMEC microvessels was below the detection limit at all timepoints.  We 
observed no plumes of solute entering the ECM associated with focal leaks, indicating tight 
junction stability. 
To assess whether the barrier function of BC1 dhBMEC microvessels was robust, we formed 
microvessels with dhBMECs derived from the iPS12, KW01 and AD6 lines.  The iPS12 line was 
derived from the cord blood of a healthy female [210].  The KW01 line was derived from a 73-
year-old male with multiple sclerosis, and the AD6 line was derived from an individual with 
Alzheimer’s disease with a PSEN1 A246E mutation.  Microvessels generated from the iPS12, 
KW01, and AD6 lines also display low solute permeability.  There were no statistically significant 
differences in Lucifer yellow, Rhodamine 123, or 10 kDa dextran permeability between BC1, 
iPS12, KW01 and AD6 microvessels on day two (p > 0.05 for all comparisons).    The barrier 
function of these four cell lines was also assessed by measuring transendothelial electrical 
resistance (TEER) in a standard transwell assay, as previously reported [196].  Day two TEER was 
2,260 ± 39 Ω cm2 for BC1s, 2260 ± 73 Ω cm2 for iPS12s, 1330 ± 343 Ω cm2 for KW01s, and 2160 
± 514 Ω cm2 for AD6s.   
To provide a comparison for the permeability in dhBMEC microvessels, we performed the same 
experiments in HUVEC microvessels.  HUVEC microvessels also display stable permeability over 
six days.  There were no statistically significant differences in permeability between day two, four 
and six for Lucifer yellow, Rhodamine 123, and 10 kDa dextran (p > 0.05 for all comparisons).  
From the phase / fluorescence overlays, it is evident that the extent of penetration of these solutes 
into the ECM was significantly larger than in the dhBMEC microvessels.  The mean permeability 
for Lucifer yellow over six days was 3.90 ± 0.16 x 10-6 cm s-1, more than 10-fold higher than in 










6 cm s-1, about 20-fold higher than in dhBMEC microvessels.  The permeability of 10 kDa dextran 
over six days was 1.23 ± 0.19 x 10-6 cm s-1.  No focal leaks were observed in HUVEC microvessels 
during solute perfusion.  A similar value for the permeability of 10 kDa dextran and the absence of 
focal leaks have previously been reported in HUVEC microvessels cultured under similar 
conditions [213].    
2.3.3.Brain microvessels display distinct endothelial cell dynamics 
The behavior of endothelial cells was assessed from analysis of phase contrast images at the 
microvessel poles (Figure 2-4).  Rates of cell proliferation, loss, and turnover were determined by 
direct counting of cell events to eliminates possible errors associated with staining markers to 
quantify mitosis and apoptosis [223]. 
In dhBMEC microvessels the proliferation rate decreased significantly over time, from 1.66 ± 0.281 
% h-1 on day two to 0.199 ± 0.064 % h-1 on day six (p < 0.0001). The cell loss rate also decreased 
significantly from 1.015 ± 0.067 % h-1 on day two to 0.334 ± 0.083 % h-1 on day six (p = 0.0004).  
The net turnover (% h-1), calculated by subtracting the rate of cell loss from the rate of proliferation, 
decreased from 0.648 ± 0.302 % h-1 on day two to -0.134 ± 0.050 % h-1 on day six (p = 0.0121); 
the resulting day six turnover was not statistically different from zero (p = 0.1146). Proliferation 
and cell loss events were equally distributed over the entire two-hour imaging window, as evident 
by linear increases in cumulative events as a function of time (r > 0.98 for each plot); while on day 
two proliferation events occurred more frequently than cell loss events, this trend reversed by day 
six. 
In HUVEC microvessels the rates of proliferation, cell loss, and turnover remained stable over six 
days (p > 0.05 for all comparisons).  HUVECs displayed lower cell rates of proliferation and loss 
than dhBMECs on day two and four (p < 0.05 for all comparisons). By day six, the rates of 











Figure 2-4. Endothelial cell dynamics of BC1 dhBMEC microvessels.  (A, B) Representative 
time-lapse images depicting cell division and cell loss, respectively.  (C-E) Rates of proliferation, 
cell loss, and turnover rate, respectively, on days 2, 4, and 6 following seeding. (F) Cumulative 
proliferative and cell loss events during imaging of BC1 dhBMEC microvessels.  (G) RMS 
displacement. (H) Representative path for a dhBMEC (blue line) and HUVEC (black line) cell on 
day 2 following seeding. (I) Scatter plot showing the change in dhBMEC position over two hours 
normalized to the initial position for all cells tracked, the average cell displacement vector (x, y) = 
(1.16 µm, 0.22 µm). (J) Scatter plots of dhBMEC cell path and RMS displacement (dotted black 
line denotes average cell diameter). (K) Number of cell neighbors. (L) Fluorescence image showing 
representative six cell neighbors of dhBMEC microvessels. (M) The frequency of change in the 
number of cell neighbors.  (N-O) Fluorescence images showing a stain for f-actin and basement 
membrane protein laminin α4 on the bottom pole of a microvessel on days 2 and 6. (P) Confocal 
cross-sections of laminin α4 on days 2 and 6.  Experiments were performed on at least three 










dhBMECs (p > 0.05 for all comparisons).  It is difficult to completely decouple endothelial cell 
behavior across both cell lines due to differences in media composition; however, high cAMP levels 
used in both microvessel medias have previously been found to reduce cell turnover [213]. 
Phase contrast images, DAPI stains, and f-actin stains confirm that the average dhBMEC area 
ranges from about 600 to 700 µm2, corresponding to an average cell diameter of ~28 µm.  This is 
a useful metric for comparing length scales of cell motion.  Root mean square (RMS) displacement 
for dHBMECs did not change over time (p > 0.05 for all comparisons) and was on average 8.72 ± 
0.75 µm over two hours of imaging.  The RMS displacement for HUVECs was not significantly 
different than dhBMECs (p > 0.05 for all comparisons), similarly remaining below 10 µm.  We 
observe that the typical dhBMEC and HUVEC displacement was less than the diameter of an 
average cell, and that the cell motility corresponds predominantly to small fluctuations in position 
within the monolayer.  There was no clear spatial directionality of cell motility, as across all 
dhBMECs the average displacement vector over two hours of imaging was 1.16 µm, 0.22 µm (x, 
y).  Furthermore, cell path length widely varied between individual dhBMECs, but was on average 
an order of magnitude higher than RMS displacement.  
To assess the spatial organization of endothelial cells within the microvessels, we determined the 
number of neighbors that share a boundary for each cell.  The average number of cell neighbors for 
both dhBMECs and HUVECs was between six and seven.  The frequency of change in number of 
cell neighbors for dhBMEC microvessels was 0.406 ± 0.054, suggesting that cells experience a 
change in number of cell neighbors once every 2.5 hours.  This frequency was the same across cell 
types and time points (p > 0.05 for all comparisons).  
To assess cytoskeletal organization, we stained dhBMEC microvessels for f-actin.  On day two, f-
actin was localized to cell-cell junctions with no preferred orientation.  After six days, we also 










they do not appear to be aligned with flow. These observations have previously been reported for 
HUVECs in 2D monolayers [221].  To assess basement membrane maturation we stained dhBMEC 
microvessels for laminin α4; we did not stain for collagen IV and fibronectin as they were used to 
coat collagen channels to promote cell adhesion.  On day two, expression was punctate, but by day 
six, laminin expression was uniform around the microvessel.   
2.3.4.P-gp inhibition 
To assess efflux activity, we measured the permeability of Rhodamine 123 with and without the p-
glycoprotein inhibitor tariquidar.  2 μM tariquidar treatment increased Rhodamine 123 permeability 
from 1.32 ± 0.16 x 10-7 cm s-1 to 2.66 ± 0.44 x 10-6 cm s-1 (p = 0.0149) (Figure 2-5).  The 
permeability of Lucifer yellow and 10 kDa dextran did not change in the presence of tariquidar (p 
> 0.05).  Rhodamine 123 accumulates within endothelial cells and results in increasing fluorescence 
intensity during permeability experiments.  The ratio of permeability calculated from the ECM (by 
excluding the lumen / intracellular compartment) and permeability calculated by the entire imaging 
frame (PECM / Ptotal) was ~0.8 for Lucifer yellow in BC1 dhBMEC and HUVEC microvessels, 
indicating negligible intracellular accumulation.   For Rhodamine 123, PECM / Ptotal was 0.749 ± 
0.022 for HUVEC microvessels, 0.203 ± 0.027 for BC1 dhBMEC microvessels, and 0.381 ± 0.031 
for tariquidar treated BC1 dhBMEC microvessels.  These results show that: (1) dhBMEC 
microvessels display greater intracellular Rhodamine 123 accumulation compared to HUVECs (as 
indicated by a lower ratio, p < 0.0001) and (2) tariquidar treatment increases the contribution of 
transcellular transport compared to intracellular accumulation compared to non-treated controls (as 
indicated by a higher ratio, p = 0.0046).  We note that Rhodamine 123 is an active mitochondrial 
stain and increased accumulation could result from a higher mitochondrial density in dhBMECs.  
The ratio of Lucifer yellow to Rhodamine 123 permeabilities (PLY / PR123) indicates the relative 











Figure 2-5. Blood-brain barrier efflux inhibition.  Microvessels were exposed to 2 µM tariquidar 
treatment for 12 hours.  (A) Phase / fluorescence overlays showing Rhodamine 123 permeability 
in BC1 dhBMEC microvessels treated with tariquidar for 12 hours.  (B) Comparison of BC1 
dhBMEC microvessel permeability with and without tariquidar treatment.  (C) The ratio of 
Rhodamine 123 permeability calculated only considering the ECM to including the ECM, lumen 
and intracellular compartments (PECM/Ptotal) in HUVEC and BC1 dhBMEC microvessels with and 
without tariquidar treatment. (D) Ratio of Lucifer yellow permeability to Rhodamine 123 
permeability (PLY / PR123).  (E) Phase contrast images of BC1 dhBMEC microvessels before and 
after tariquidar treatment.  Data collected from at least three BC1 dhBMEC microvessels, from at 
least two independent differentiations for each experimental condition.  
 
 
PR123 of ~1.9 and ~1.3, respectively.  With 12 hours of tariquidar perfusion PLY / PR123 was < 1 
suggesting an increase in the transcellular transport (no statistical significance, p > 0.05).  
Additionally, 12 hours of exposure did not result in apparent cytotoxicity as observed by preserved 
barrier function and microvessel structure. 
2.3.5.Hyperosmolar blood-brain barrier opening 
To model a protocol used clinically for transient opening of the BBB, on day two we introduced 
mannitol (1.4 M) to the upper fluid reservoir for five minutes and then immediately perfused brain 
microvessels with Lucifer yellow and 10 kDa dextran to study changes in permeability (Figure 











Figure 2-6. Hyperosmolar blood-brain barrier opening. On day two, 1.4 M mannitol was 
introduced into the upper fluid reservoir for five minutes, followed by Lucifer yellow and 10 kDa 
dextran.  (A) Phase contrast images at the pole of a BC1 dhBMEC microvessel following mannitol 
exposure.  t = 0 represents the frame prior to arrival of mannitol into the lumen.  Corresponding 
phase / fluorescence overlays for (B) Lucifer yellow and (C) 10 kDa dextran.  Plumes of 10kDa 
dextran entering the ECM are marked with arrows.  (D) Day two permeability increases with 
mannitol exposure.  (E) Vacuoles per cell over two hours of imaging.  (F) Fluorescence image 
showing f-actin phalloidin stain at the pole of a microvessel following mannitol exposure.  Data 
collected from at least three BC1 dhBMEC microvessels, from at least two independent 
differentiations for each experimental condition. 
 
the ECM, as well as focal leaks indicating disruption of endothelial cell-cell junctions.  Following 
mannitol injection, the average permeability of Lucifer yellow was 3.67 ± 1.39 x 10-6 cm s-1, 
approximately 15-fold higher than homeostatic brain microvessels on day two (p = 0.0025).   
Similarly, 10 kDa dextran permeability increased to 2.32 ± 0.86 x 10-6 cm s-1 (p = 0.0047).  Recall 










10 kDa dextran permeability was also approximately two-fold higher than the baseline permeability 
in HUVEC microvessels (1.23 ± 0.19 x 10-6 cm s-1), although not statistically significant (p > 0.05).    
The loss of intracellular water following mannitol exposure is associated with formation of 
vacuoles [224], which are observed in phase contrast images.  The number of vacuoles plateaued 
over approximately 20 minutes following injection of mannitol, reaching a maximum value of 
approximately six per cell.   Lucifer yellow and 10 kDa dextran remain excluded from endothelial 
cells (images not shown) indicating that vacuoles are not formed by invagination of the plasma 
membrane.  Phalloidin staining following mannitol exposure shows increased stress fiber formation 
indicating actin cytoskeleton disruption.   
2.3.6.Brain microvessels are responsive to cytokine activation 
To assess the feasibility that our model can be used to visualize immune cell interactions under 
inflammatory conditions, we stimulated microvessels with 10 ng mL-1 TNFα for 12 hours.  
Exposure of dhBMEC microvessels to TNFα resulted in upregulation of adhesion molecules 
ICAM-1 and VCAM-1 (Figure 2-7).  In non-treated microvessels ICAM-1 and VCAM-1 
expression was punctate, however, following TNFα exposure expression of these adhesion 
molecules was uniform across the microvessel lumen.  Treatment with TNFα did not alter the 
permeability of Lucifer yellow, Rhodamine 123, or 10 kDa dextran when compared to control 
microvessels (p > 0.05 for all comparisons).  Fluorescently labeled human peripheral blood 
mononuclear cells (PBMCs) were perfused in the microvessels for 30 minutes at a shear stress of 
~1 dyne cm-2.  Following a five-minute wash out, adherent PBMCs were clearly visible attached to 
the endothelium.  Microvessels exposed to TNFα showed higher numbers of adherent PBMCs (23.0 
cells cm-1) as compared to control microvessels (1.75 cells cm-1) (p < 0.0001).  While 
transendothelial migration events were not observed during the experiments, microvessels exposed 











Figure 2-7. Brain post-capillary venular model of leukocyte adhesion during 
inflammation.(A) Fluorescence images of the cross section of BC1 microvessels showing 
upregulation of surface adhesion markers (VCAM-1, ICAM-1) following 12-hour cytokine 
treatment with 10 ng mL-1 TNF-α.  (B) Permeability of Lucifer yellow, Rhodamine 123, and 10 
kDa dextran in BC1 dhBMEC microvessels following treatment with TNF-α.  (C) Representative 
fluorescence images showing PBMCs adhered to the bottom pole of BC1 dhBMEC microvessels 
with and without cytokine activation.  (D) Adhesion of human peripheral blood mononuclear cells 
(PBMCs) increases with TNF-α exposure.  (E) Phase contrast image showing macroscopic 




We have characterized the structure and barrier function of 150 µm diameter microvessels formed 
using human iPSC-derived BMECs (dhBMECs).   Physiological barrier function was established 
after only two days and maintained for at least four additional days, enabling time course studies 
of biologically- and clinically-relevant perturbations.    
One of the most important functions of the BBB is to restrict access to the brain.  Lucifer yellow 
permeability of BC1 dhBMEC microvessels was 2.84 ± 0.41 x 10-7 cm s-1 over six days, very close 
to values that we have previously reported for dhBMEC monolayers in a 2D transwell assay [196], 










in rats.[225]  In addition, the permeability of 10 kDa dextran remained below the detection limit, 
showing that dhBMEC microvessels effectively block transport of large molecular weight solutes.  
Numerous studies have shown that dyes (i.e. Evans Blue), which bind to albumin (66.5 kDa), are 
excluded from the brain implying extremely low permeability [226].  Similarly, four hours after 
systemic injection of 20 kDa dextran, no dye extravasation was found in the brain parenchyma in 
a hamster model [227].  However, more recent in vivo imaging in rat pial post-capillary venules 
have reported finite and relatively high permeabilities of about 1 - 2 x 10-7 cm s-1 for 10 - 70 kDa 
dextrans [228, 229], which is inconsistent with other results showing restricted transport of large 
molecular weight solutes across the BBB.  Reconciling these differences in in vivo permeabilities, 
which may be due to the substantial regional BBB heterogeneity [230], is important towards 
validating tissue-engineered models. 
Physiological values for TEER are thought to be in the range of 1,500 - 8,000 Ω cm2 [190-193].  
As Lucifer yellow permeability in dhBMEC microvessels was the same as values obtained in 
transwell assays (where TEER was above 1,500 Ω cm2), this implies that the transendothelial 
electrical resistance (TEER) was also likely similar, as previously shown for dhBMECs cultured 
on hydrogel materials in 2D [198].  Together, these results suggest that we have achieved 
physiological barrier function within perfusable 3D microvessels.  A further implication of these 
results is that physiological barrier function is dependent on the ability of the hBMECs to form 
tight junctions, and that other cell types, such as astrocytes and pericytes, are not required for 
establishment of barrier function.  Evidence for this hypothesis comes primarily from in vitro 
transwell experiments where the presence of astrocytes or pericytes (or astrocyte extract) in the 
basolateral chamber increases TEER [231-237].  However, these experiments were performed with 
BMECs displaying non-physiological TEER (< 1,500 Ω cm2).  In most of these studies, TEER 










Other strategies for engineering microvessels using primary BMECs, regardless of inclusion of 
supporting cell types (i.e. pericytes and astrocytes), result in permeabilities still significantly higher 
than values reported here [186-189].  For example, in one model incorporating primary human 
BMECs, astrocytes, and pericytes, the permeability of 3 kDa dextran was reported to be 2 - 4 x 
10−6 cm s-1 [187].  As acknowledged by the authors, this high permeability for a large molecule did 
not recapitulate BBB barrier function, and was likely associated with their reported low TEER 
values of the primary BMECs (40 - 50 Ω cm2).  Therefore, we hypothesize that rather than being 
responsible for maintenance of barrier function, it is likely that these supporting cells provide 
factors that promote recovery of barrier function towards physiological values. This hypothesis is 
further supported by studies that utilize astrocytes and/or pericytes to improve the barrier function 
of non-brain specific endothelial cells (HUVEC or iPSC-derived) in microvascular networks [180, 
209]. 
In addition to forming functional microvessels from iPSCs from two healthy individuals (BC1 and 
iPS12), we also created microvessels from iPSCs from an individual with multiple sclerosis 
(KW01), and an individual with Alzheimer’s disease (AD6).  Disruption of the BBB is associated 
with many neurodegenerative disorders and may manifest through non-cell autonomous toxicity of 
endothelial cells [131, 179].  Recently, iPSC-derived BMECs from individuals with Huntington’s 
disease (HD) were found to display abnormal barrier function, which may contribute to HD 
pathology [137].  Here we show that the barrier function of microvessels formed from dhBMECs 
from individuals with AD and MS show no difference in permeability to Lucifer yellow, 
Rhodamine 123, and 10 kDa dextran compared to iPSCs from healthy individuals.  While these 
results suggest that the mutations associated with AD and MS in these iPSC lines do not induce 










2.4.2.Endothelial cell dynamics  
Turnover is an important but often overlooked parameter in benchmarking tissue engineered 
vascular models.  The turnover of BMECs in the human brain has not been reported, and there are 
only limited data from animal models [32, 238, 239] and other tissue beds [240, 241].  Similarly, 
there are very few studies on the effect of disease (i.e. brain cancer, neurogenerative disease) on 
brain endothelial cell turnover.   Over six days, the turnover of dhBMECs in BC1 microvessels 
decreases to reach a net turnover rate close to zero.  While the proliferation rate was less than values 
previously reported in 2D dhBMEC monolayers cultured on glass under similar shear stress (0.35 
% h-1), the rate of cell loss was significantly higher than in 2D (0.01% h-1) [220].  Results from 
thymidine labeling studies in mice suggest proliferation rates for BMECs of about 0.04 % h-1 [238], 
an order of magnitude or more lower than endothelial cells in other tissues [240, 241].  Two-photon 
intravital microscopy studies in adult mice have shown: (1) no change in capillary segment 
diameter, capillary segment length, and the position of branch points over about 30 days [32], and 
(2) no detectable endothelial cell division over ten days based on BrdU labeling of cortical 
microvessels [239].  These results suggest that the rates of cell proliferation and loss need to be 
further decreased to achieve physiological turnover.  
Tracking of dhBMECs in microvessels showed that 96.5% of cells do not move more than an 
average cell diameter (28 µm) over two hours, as we have shown previously in 2D dhBMEC 
monolayers [220].  The maximum number of neighbors for an isotropic object in 2D is six, 
corresponding to a hexagonal or close-packed lattice, whereas for a random distribution the number 
of cell neighbors is expected to be five.  In dhBMEC microvessels, the average number of neighbors 
for each cell was between six and seven.  As we have hypothesized previously, a close packed 
network of cells (hexagons) is a way to minimize the total length of cell-cell junctions per unit 










on day six.  dhBMECs were relatively rounded, with a circularity of about 0.73 and an inverse 
aspect ratio of about 0.57, similar to values obtained in 2D under static conditions [220], suggesting 
that the circularity and orientation of dhBMECs was independent of geometry or shear stress. The 
number of cell neighbors changed once approximately every 2.5 hours for dhBMECs; this rate of 
change was not due to turnover since the rates of proliferation (0.19 % h-1) and cell loss (0.33 % h-
1) mean that the average time for loss / gain of a neighboring cell is about 50 hours.  Similarly, this 
change was not due to migration of cells within the monolayer because most cells do not move 
more than one cell length.  Based on observations from phase contrast videos, we suggest that the 
changes in neighboring cells are associated with formation and loss of triple junctions that result in 
dynamic changes in the number of neighbors.   Whether these transient changes in the number of 
cell neighbors play a significant role in determining paracellular permeability remains to be 
established.  
The basement membrane is an important component of the BBB, comprising several proteins 
including collagen IV, fibronectin, and laminin [243, 244].  Time course actin and laminin stains 
indicate that dhBMECs are actively modify the surrounding ECM and reorganizing their actin 
cytoskeleton; the links between these changes and cell behavior remain to be established.  
2.4.3.Efflux inhibition 
ATP-binding cassette (ABC) efflux transporters including P-glycoprotein (P-gp), actively transport 
many lipophilic compounds out of brain microvascular endothelial cells, limiting their penetration 
into the CNS [245].  Important P-gp substrates include anticancer drugs, immunosuppressive 
agents, antibiotics, corticoids, antivirals, antidepressants, antiepileptic drugs, and many other 
therapeutics [246].  Thus, modulation of efflux transporters represents a key strategy to improve 
CNS drug delivery.  However, P-gp inhibition has had limited clinical success due to issues with 










inhibition have several limitations.  In vitro models, such as transwell assays or substrate 
accumulation assays, enable confirmation of the polarization of efflux transporters to the luminal 
membrane but do not provide direct visualization of transport phenomena. In contrast, the 
pharmacokinetics in vivo in animal model do not precisely match that of humans [248-250]. 
Tariquidar is a potent third generation P-gp inhibitor that has undergone multiple preclinical trials 
to improve drug delivery to the brain [251-253].  Tariquidar plasma concentrations between 2 - 3 
μM are utilized to effectively limit P-gp efflux.  In our model, 12-hour perfusion of 2 μM tariquidar 
increased Rhodamine 123 permeability two-fold, while disruptions in paracellular permeability 
were not observed.  In healthy humans, continuous infusion of tariquidar, which was predicted to 
achieve near complete inhibition of p-glycoprotein, increased the verapamil distribution volume 
2.73-fold, similar to the results reported here [252]. 
2.4.4.Blood-brain barrier opening 
Many techniques have emerged to modulate BBB permeability for delivery of therapeutic 
compounds, including: focused ultrasound [254], enterotoxin analogs [255], siRNA delivery 
systems [256], and exosomes [257], however, few have been translated to the clinic.  Systemic 
intravenous injection of the hyperosmolar agent mannitol is used clinically to reduce cerebral 
edema in a wide range of acute conditions [258].  However, bolus intra-arterial injection over 1 - 2 
minutes at a high concentration (close to the solubility limit of around 1.4 M), results in endothelial 
cell shrinkage that is sufficient to induce transient opening of the BBB [259].  Hyperosmolar BBB 
opening has been used to improve delivery of chemotherapeutics, stem cells, and viral vectors into 
the brain [260-262].  Despite the more than 100-year history of research into hyperosmotic agents 
in the brain and the renewed interest in image-guided opening of the BBB [263], the procedure is 
not reproducible [264] highlighting the need for mechanistic studies at the cellular level.  










structure and function of brain vasculature. Several major arteries supply the brain and regulation 
of blood flow by the Circle of Willis results in variable and irreproducible mixing and distribution 
of solutes throughout the brain.  Animal models are valuable for studying these phenomena; 
however, there are substantial differences in vascular anatomy and cerebral blood flow between 
humans and animal models [265, 266]. Thus, in vitro models provide the opportunity to study 
hyperosmotic therapy under controlled conditions.   
In response to a five-minute bolus of 1.4 M mannitol, we observed a 15-fold increase in the 
permeability of Lucifer yellow, confirming blood-brain barrier opening.  In addition, the 
permeability of 10 kDa Dextran, which was below the detection limit under baseline conditions, 
increased to 10-fold higher than Lucifer yellow under baseline conditions.  Over two hours of 
imaging, barrier function remained disrupted, although some leakage of dye was transient.  
Previous studies have found that mannitol exposure results in transient reductions in TEER both  
in vivo [190] and in in vitro culture of primary brain microvascular endothelial cells [267].  From 
histological studies, brain penetration of herpes simplex virus following hyperosmolar BBB 
opening suggests a transient defect size up to 120 nm [268].   In our model, mannitol results in 
leakage of 10 kDa dextran, which has a hydrodynamic size of 4.8 nm [269].  Future studies will 
explore the reversibility of BBB opening and the dynamics of pore formation.  Additionally, 
hyperosmotic stress resulted in formation of vacuoles within endothelial cells.   Vacuole formation 
is a mechanism to buffer cells against increases in ion concentration that occurs due to the 
associated decrease in cell volume.  Vacuoles formation plateaus after only 20 minutes and remains 
steady over the subsequent 1.5 hours (despite an only transient exposure to mannitol).  Fluorescent 
solutes were not found to accumulate within the cells suggesting that vacuoles are not direct 











Studies of leukocyte interactions in the cerebrovasculature are usually performed in the 
autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis or in 2D in vitro models 
[270, 271].  We show that it is possible to study leukocyte dynamics within 3D models of human 
post-capillary venules, which supports visualization in a well-controlled environment [272].  
Immune trafficking across the BBB is low under physiological conditions, however, increased 
infiltration is implicated in neurological disease [273].  Endothelial ICAM-1 and VCAM-1 
expression promotes leukocyte adhesion [274, 275], an early step in extravasation, which occurs 
preferentially in PCVs of the brain [203-205].  In BC1 dhBMEC microvessels, exposure to 
inflammatory cytokine TNFα resulted in upregulation of VCAM-1 and ICAM-1, and 
corresponding increased adhesion of human peripheral blood mononuclear cells.   
We also found that TNFα activation resulted in no change in barrier function.  This observation is 
contradictory to results from in vitro 2D models [276-279], existing 3D BBB models [187, 188], 
and in vivo animal models [280], all of which report increased permeability of BMECs exposed to 
TNFα.  However, as described previously, in vitro models utilizing BMECs with non-physiological 
TEER may be more susceptible to disruptive changes in barrier function [281]. Therefore, our 
results suggest that TNFα stimulation alone, without other blood components and conditions 
associated with an immune response, is insufficient to induce BBB disruption. Interestingly, 24 
hours after TNFα activation and PBMC adhesion studies, microvessels displayed macroscopic 
breakdown suggesting a possible role of cytokine secretion. In our model, no transendothelial 
migration events were observed, presumably since there was change in barrier function, but also 
potentially due to the restrictive nature of a dense cross-linked collagen hydrogel.  Although they 










potential advantage of in vitro models to deconvolve complex processes occurring during 
inflammation. 
2.5.Conclusions 
We report on barrier function and endothelial cell behavior of human iPSC-derived blood-brain 
barrier microvessels resembling in vivo post-capillary venules.   Microvessels are generated from 
multiple iPS cell lines and display localization of tight junction proteins, and expression of key 
transporters and efflux pumps.  Physiological barrier function is achieved within two days, requires 
no co-cultured cells, and is maintained for at least four days.  Over the course of six days, 
endothelial cells reach quiescence and develop a uniform basement membrane.  We demonstrate 
successful modulation of both transcellular and paracellular permeability using P-gp inhibitor 
tariquidar and hyperosmolar agent mannitol, respectively.  Cytokine activation using TNFα 
resulted in upregulation of leukocyte adhesion molecules (VCAM-1 and ICAM-1) and increased 
leukocyte adhesion, but resulted in no change in permeability suggesting that activation alone is 
insufficient to induce BBB disruption.  Human iPSC-derived blood-brain barrier microvessels 
serve as a robust patient-specific platform to study transport phenomena and endothelial cell 
behavior during health and disease. 
Chapter 3. Modeling hyperosmotic blood–brain barrier opening within human 
tissue-engineered in vitro brain microvessels 
A version of this chapter is published in Journal of Cerebral Blood Flow & Metabolism 39 (2019) 
1413-1432. [282] 
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3.1.Introduction 
The human blood-brain barrier (BBB) restricts delivery of therapeutics to the brain for treatment 
of CNS disease [283].  Tight junctions (TJs) between adjacent brain microvascular endothelial cells 
(BMECs) restrict paracellular transport of solutes, while expression of efflux pumps regulates 
transcellular transport [3].  Therefore, drug therapies are largely limited to small lipophilic 
molecules that have moderate to high rates of passive transport across BMEC membranes.  
However, reversible disruption of TJs can be exploited to transiently increase bioavailability of a 
broad range of therapeutics into the brain [284, 285]. 
Intra-arterial (IA) infusion of hyperosmotic agents, such as mannitol, is one approach for transient 
BBB opening (BBBO) [259].  Drug delivery techniques based on IA administration have distinct 
advantages including high regional drug concentration, high spatial selectivity, rapid onset of 
action, and limited systemic dose [286].   Systemic intravenous (IV) administration of mannitol is 
widely used in the clinic to reduce cerebral edema, however, IA injection at a sufficiently high 
concentration (close to the solubility limit of around 1.4 M), causes BMEC shrinkage which is 
sufficient to induce transient BBBO [259, 287, 288].  This technique has been used for several 
decades in both preclinical models and clinical studies to improve delivery of chemotherapeutics, 
stem cells, and gene vectors [260-262, 289-293].  The reproducibility of BBBO can be difficult to 
control due to dilution of the injected dose by collateral blood supply in the Circle of Willis, as well 
as more distally in microcirculation [265, 294]. Advances in image-guided insertion of catheters 
beyond the Circle of Willis into specific locations in the cerebrovasculature have renewed interest 










Although hyperosmotic therapies have been studied for more than 100 years [297], the mechanism 
of action is not fully elucidated.  The current model of hyperosmotic BBBO assumes that water 
loss from BMECs into the capillary lumen induces vasodilation, resulting in a homogeneous 
increase in BBB permeability [259].  Much of what we know about hyperosmotic therapies relies 
on magnetic resonance imaging (MRI) and positron emission tomography (PET) [295].  However, 
these techniques are not well suited for interrogating mechanisms at the cellular level.  Here, we 
report on real-time imaging of hyperosmotic BBBO on the scale of individual cells in a tissue-
engineered microvessel model of the cerebrovasculature incorporating stem cell-derived human 
BMECs (dhBMECs) [26, 181, 198].  From fluorescence imaging of different molecular weight 
solutes following exposure to different mannitol doses, we assess spatial and temporal changes in 
barrier function, while from phase contrast imaging we assess changes in BMEC structure.  The 
key observations are: (1) mannitol causes transient focal leaks that result in a significant increase 
in the overall permeability, (2) the focal leaks occur at small (1 – 2 µm) sub-cellular disruptions in 
the endothelium, (3) the global TJ network is unaffected by mannitol, and (4) the increase in 
permeability is due solely to paracellular transport.  We establish the timeline of events following 
hyperosmotic BBBO, including spatially heterogenous increases in paracellular permeability and 
BMEC vacuolation.  Finally, we show that bFGF has an important role in modulating the 
susceptibility to BBBO and recovery.  Our results highlight the ability to evaluate drug delivery 
mechanisms using a tissue-engineered microvessel model of the human BBB. 
3.2.Materials and Methods 
3.2.1.MRI during BBBO in mice 
Animal experiments were performed in accordance with guidelines for the care and use of 
laboratory animals approved by the Institutional Animal Care and Use Committee of Johns Hopkins 










Service (PHS) policy, and were performed in accordance with ARRIVE guidelines.  Four SCID 
mice (male, 6-8 weeks old, 20-25 g, Jackson Laboratory) were used in this study.  Carotid artery 
catheterization was performed as previously described [295], before mice were transferred to a 
Bruker 11.7 T MRI scanner.  T1 (TR/TE 350/6.7ms)-weighted and dynamic T1 imaging (TR/TE 
2000/3.5ms, field of view = 14×14 mm, acquisition time = 8 s and 40 repetitions) of the brain was 
acquired. 1.4 M mannitol (Hospira) was administered intra-arterially for 1 minute at an injection 
speed of 0.15 ml min-1.  Five minutes after mannitol dosing, mice received 0.07 mL of Gadoteridol 
(Gd; Bracco Diagnostics) intraperitoneally.  T1-weighted images were obtained 5 minutes post-Gd 
injection to visualize BBB integrity; for dynamic monitoring of BBBO, T1 scans were acquired 
during and after a 1-minute infusion of 1.4 M mannitol mixed with Gd (5.6 mg/mL).   
1 mm x 1 mm regions of interest (ROIs) were drawn on MRI images corresponding to: (1) 
contralateral hippocampus, (2) contralateral cerebral cortex, (3) ipsilateral cerebral cortex, and (4) 
ipsilateral hippocampus.  The Gd contrast ratio post-mannitol versus pre-mannitol was computed 
using ImageJ (NIH) and normalized to contralateral hippocampus (ROI 1; where BBBO does not 
occur).  For dynamic T1 measurements identical ROIs were used and contrast intensity (normalized 
between 0 and 1 for ROI 4) plotted over five minutes.   
3.2.2.Blood-brain barrier microvessel fabrication 
Human brain microvascular endothelial cells (dhBMECs) were differentiated from induced 
pluripotent stem cells (iPSCs) as previously reported [181, 196].  The BC1 iPSC line derived from 
a healthy individual was used for all experiments [210].  BC1 dhBMECs show transendothelial 
electrical resistance (TEER) values above 1500 Ω cm2 in two-dimensional culture, when cultured 
in media supplemented with retinoic acid [196, 298].  
BBB microvessels were fabricated as previously reported [181, 198].  The microfluidic device 










cross-linked type I collagen hydrogel contained in a polydimethylsiloxane housing.  Inlet and outlet 
fluid reservoirs are connected to a flow loop to maintain a shear stress of approximately 4 dyne cm-
2 [181, 198].  Functional BBB microvessels with physiological barrier function are formed two 
days following seeding dhBMECs in the microfluidic device [181, 198].  After establishing barrier 
function (defined as day 0), timelapse imaging experiments were initiated.  
Microvessels were perfused with media (denoted as BBB microvessel media): human endothelial 
cell serum-free media (Life Technologies) supplemented with 1% human platelet poor derived 
serum (Sigma), 1% penicillin-streptomycin (Life Technologies), 400 µM db-cAMP (Sigma), 20 
µM phosphodiesterase inhibitor Ro-20-1724 (Calbiochem), 3% 70 kDa dextran (Sigma), and 10 
µM ROCK inhibitor Y27632 (ATCC, only supplemented for first 24 hours after seeding).  Where 
noted, 20 ng mL-1 recombinant human basic fibroblast growth factor (R&D systems; 146 aa, bFGF) 
was supplemented for either the initial 24 hours of device perfusion (day -2 to day -1) or for 48 
hours following imaging experiments (day 0 to day 2). 
3.2.3.Live-cell imaging of BBB opening 
The experimental design and timeline of dosing and assessment of barrier function during live-cell 
imaging is summarized in Figure 3-1.  Microvessels were maintained at 37 ˚C and 5% CO2 in a 
live-cell chamber, and imaged on an inverted microscope (Nikon Eclipse TiE).  Epifluorescence 
illumination was provided by an X-Cite 120LEDBoost (Excelitas Technologies).  On day 0 (two 
days after seeding microvessels), media was removed from the upper reservoir and replaced with 
1.4 M mannitol (Sigma) and 5 µM Sodium fluorescein (Sigma) prepared in BBB microvessel media 
for two, five, or ten minutes depending on the mannitol dose.  After dosing, the upper reservoir was 
replaced with BBB microvessel media containing 200 µM Lucifer yellow (CH dilithium salt; LY) 
(Sigma) and 2 µM Alexa Fluor647-conjugated 10 kDa dextran (Thermo Fisher).  A NIS Elements 











Figure 3-1. Live-cell imaging experimental design and timeline.Timeline over four days.  
Devices are seeded with dhBMECs (day -2) and form into BBB microvessels over two days.  On 
day 0, microvessels are dosed with or without mannitol and imaging is conducted.  On day 2 (48 
hours later) imaging is conducted again.  bFGF treatment is applied for the initial 24 hours after 
seeding, or for 48 hours after day 0 imaging.  (b) Fluorescein and mannitol are added to the upper 
reservoir at time -2 to -10 minutes.  Next, Lucifer yellow and 10 kDa dextran are added and the 
microfluidic device is immediately imaged for two hours.  Afterwards, microvessels are re-exposed 
to fluorescein for one hour.  (c)  2, 5 and 10-minute mannitol doses are visible in the microvessel 
as fluorescein fluorescence shortly after imaging begins.  Fluorescein focal leaks are counted during 
mannitol dosing and during fluorescein re-administration.  Once, 10 kDa dextran enters the 
microvessel lumen focal leaks are counted over the remaining 2-hour imaging window.  Lucifer 
yellow (LY) permeability is calculated over 20 minutes following luminal filling.  BMEC 
vacuolation is counted over the entire 2-hour imaging window. 
 
kDa dextran to the upper reservoir.  Phase contrast and fluorescence images were acquired every 
two minutes for two hours (61 frames).  At every time point six images were collected: (1) a phase 
contrast image of the top of the microvessel, (2-5) phase contrast and fluorescence images of the 
microvessel midplane, and (6) a phase contrast image of the bottom of the microvessel.  To 
independently excite and collect the emission from each fluorophore, three filter cubes were used: 










exposure), and Chroma 41008 for dextran (200 ms exposure).  The total image area was 
approximately 8.2 mm x 0.67 mm, corresponding to ten adjacent frames using a 10x objective.   
Mannitol (MW 182.2) dosing was indirectly monitored using co-administered fluorescein (MW 
376.3 Da), a small fluorescent compound that does not exhibit intracellular accumulation.  
Fluorescein begins filling the microvessel several minutes after imaging is initiated due to transit 
within 40 cm long tubing, which connects the upper reservoir and microvessel (Figure 3-5, A).  
Since convective flux is proportional to fluid velocity and not dependent on the physicochemical 
properties of a solute, it is reasonable to assume that mannitol and fluorescein are transported at the 
same rate; therefore, the fluorescein intensity can be used as a proxy to identify the duration and 
maximum of the mannitol dose.  After two hours of imaging, microvessels were re-perfused with 
fluorescein for one hour to monitor recovery of barrier function. 
3.2.4.Spatial permeability analysis 
Analysis is summarized in Figure 3-2.  Large images were sectioned into ten regions of interest 
(ROIs), each with dimensions of 820 µm x 670 µm.  Time course fluorescence intensity profiles of 
Lucifer yellow were obtained using ImageJ.  Microvessel permeability (cm s-1) was calculated as 
P = (d/4)(1/ΔI)(dI/dt), where d is the vessel diameter, ΔI is the increase in fluorescence intensity 
upon luminal filling, and (dI/dt)0 is the rate of increase in fluorescence intensity as the solute is 
transported across the endothelium into the surrounding matrix [216, 217].  The rate of increase of 
fluorescence intensity, from which the permeability is calculated, was determined from a linear 
least squares fit over twenty minutes following luminal filling.  Lucifer yellow permeability was 
calculated for each of the ten ROIs, with the minimum across all ROIs reported as Pmin(LY).  Five 
adjacent ROIs with the lowest mean permeability were used to analyze spatial heterogeneity of 










interstitial leakage of dye into the hydrogel from the inlet and outlet, which artificially increases 
permeability values. 
Focal leaks induced by mannitol were manually counted in ImageJ.  Focal leaks appear as radial 
extravascular plumes of fluorescence due to diffusion of dye into the hydrogel from the leakage 
site.  Focal leaks were counted over the initial dosing of mannitol and over the one-hour fluorescein 
re-administration.  In the 2 hours following dosing, the x-position along microvessels (from 0 to 
8,200 µm) and time of appearance of individual 10 kDa dextran focal leaks were recorded.  The 
total number of 10 kDa dextran focal leaks during two hours following dosing was normalized to 
microvessel length (# cm-1).   To assess penetration of 10 kDa dextran into the surrounding matrix, 
the fluorescence intensity was determined in the five adjacent ROIs with the lowest mean 
permeability excluding the microvessel lumen, corresponding to two-thirds of the imaging frame 
(total area = 1.83 mm2).  Within this region, the normalized cumulative and instantaneous change 
in fluorescence intensity was plotted as a proxy for drug extravasation. 
 
Figure 3-2. Spatial permeability analysis.  (a) Microvessels are sectioned into ten regions of 
interest (ROIs).  (b) Fluorescence is plotted over two hours for each ROI.  (c) Permeability is 
extrapolated from the shape of the curve, critical inputs are the jump in fluorescence intensity due 
to luminal filling (ΔI), the rate of increase in fluorescence after filling (dI/dt) and the microvessel 











3.2.5.Phase contrast analysis 
Structural changes observed after exposure to mannitol (i.e. intracellular vacuoles) were counted 
in ImageJ using time-lapse phase contrast images at the microvessel poles cropped to an area of 
twenty cells; the vacuole count was then normalized to the number of cells (# cell-1).  Vacuole 
quantification was verified by comparison to the corresponding fluorescence images following 
treatment with 2 µM Calcein AM (ThermoFisher), which stains all intracellular compartments 
besides vacuoles (Figure 3-7, A).  Vacuole density did not vary substantially along the x-axis of 
microvessels, justifying sampling of a single region containing twenty cells (Figure 3-7, B). 
To probe vacuole localization and function, four fluorescence assays were used:  2 µM Calcein AM 
for live cells, 4 µM ethidium homodimer-1 (ThermoFisher) for dead/dying cells, 2 µg mL-1 Hoechst 
33342 (ThermoFisher) for nuclei, and pHrodo™ Green AM Intracellular pH Indicator 
(ThermoFisher) for intracellular pH (following manufacturer suggested protocols).  For these 
experiments, microvessels were: (1) washed with live-cell imaging solution (LCIS; ThermoFisher) 
for 5 minutes, (2) stained at 37 ˚C for 30 minutes, (3) washed with LCIS for 5 minutes, and (4) 
imaged as previously described. 
Cell loss events were recorded from time-lapse imaging at the microvessel midplane.  These events 
are visible as BMECs balling-up and detaching from the endothelium.  Events were normalized to 
the length of microvessel, based on analysis within representative ~465 μm long microvessel image 
sections.   Cell density was determined by manual counting in a 32,000 μm2 area at the pole region 
of a microvessel (~100 cells). 
3.2.6.Confocal and epifluorescence imaging of hyperosmotic BBB opening 
Blood-brain barrier microvessels were constructed using the WTC iPSC line with CRISPR-edited 
tagging of zona occludens-1 (ZO1) with enhanced green fluorescent protein (EGFP) [299].  5-










Lucifer yellow were excluded from experiments due to fluorescence overlap with the fluorescently-
tagged ZO1.  Instead, 10 kDa dextran was supplemented within the brain microvessel media during 
and after mannitol dosing to monitor formation and recovery of focal leaks.  10× epifluorescence 
and 40× confocal images were collected as previously described [300]. 
3.2.7.bFGF pre-treatment in two-dimensional assays 
Upon completion of the differentiation, dhBMECs were singularized using warm Accutase for 10 
minutes.  Corning® Transwell® polyester membrane cell culture inserts (1.12 cm2 area, 0.4 µm 
pore size) and eight-chambered borosilicate cover glass wells (Lab Tek) were seeded at 1 × 106 
cells cm-2.  All surfaces were coated overnight with 50 µg mL-1 human placental collagen IV 
(Sigma) and 25 µg mL-1 fibronectin from human plasma (Sigma).  Two cell culture medias were 
tested: (1) BBB microvessel media (as outlined in methods) and (2) BBB microvessel media 
supplemented with 20 ng mL-1 recombinant human basic fibroblast growth factor.  TEER 
recordings and immunocytochemistry were conducted 48 hours after plating on transwells (day 0) 
as previously described [196].  The density of DAPI-stained nuclei was calculated using particle 
analysis in ImageJ.  Normalized fluorescence intensity of 10× images of zona occludens-1 (ZO1) 
or claudin-5 stained monolayers was used as a proxy for protein expression. 
3.2.8.Statistical analysis 
All statistical analysis was performed using Prism ver. 8 (GraphPad).  Metrics are presented as 
mean ± standard deviation (SD).  The principle statistical tests used were a student’s unpaired t-
test (two-tailed with unequal variance) for comparison of two groups, and an analysis of variance 
(ANOVA) for comparison of three or more groups.  Reported p-values were multiplicity adjusted 
using a Tukey test.  Differences were considered statistically significant for p < 0.05, with the 










experimental metrics, the beginning of the mannitol dose is designated as t = 0 and the half-time 
represents the time following dosing at which the metric reaches half its maximum value.   
3.3.Results 
3.3.1.Hyperosmotic blood-brain barrier opening in mice 
To establish a clinically relevant comparison for in vitro experiments, in vivo measurements of 
BBBO following mannitol dosing were performed in a mouse model.  Contrast enhanced T1 MRI, 
a standard technique for monitoring BBB status both clinically and in animal models [295], was 
used to imaging of BBBO following dosing with mannitol.  At hemodynamically safe IA infusion 
rates, consistent BBBO occurs in subcortical brain structures (primarily the hippocampus), while 
the cerebral cortex and the contralateral brain regions are not reproducibly opened (Figure 3-3, A).  
The Gadoteridol (Gd) contrast enhancement after mannitol dosing (compared to the value to before 
dosing) and normalized to the unaffected brain ROI, shows robust opening in the ipsilateral 
hippocampus (> 2-fold increase) compared to other regions (p < 0.01 for each comparison) (Figure 
3-3, B).  Due to the relatively low spatial resolution of MRI, opening appears to result in a uniform 
increase in permeability.  Additionally, high spatial resolution using multiphoton microscopy is not 
possible in mice as BBBO is not reproductively observed in superficial brain regions [295]. 
A 1-minute injection of mannitol, along with Gd, during real-time T1 MRI demonstrates the 
temporal and spatial signature of BBBO in the mouse brain (Figure 3-3, C).  Analysis of the 
ipsilateral hippocampus (ROI 4) shows that BBBO occurs shortly after cessation of mannitol 
infusion (less than one minute later) (Figure 3-3, D).  Additionally, while MRI enables non-invasive 
assessment of BBBO, precise calculations of vascular permeability are complicated because 














Figure 3-3. Hyperosmotic BBB opening in mice. (a) T1 magnetic resonance (MR) images were 
acquired before 1-minute 1.4 M mannitol infusion and 5 minutes after subsequent Gadoteridol (Gd) 
injection.  (b) The ratio of Gd contrast post- and pre-mannitol exposure (normalized to ROI 1).  The 
ipsilateral hippocampus displays Gd enhancement, while other regions do not. (c) T1 images during 
and after a 1-minute 1.4 M mannitol injection with Gd.  (d) Dynamics of normalized Gd contrast 
across ROIs; only the ipsilateral hippocampus (ROI 4) displays significant enhancement, which 
occurs rapidly following cessation of mannitol infusion.  Pre/Post T1 (n = 4 mice), dynamic T1 (n 
= 1 mouse).  
 
3.3.2.Mannitol induces spatially heterogenous and dose-dependent increases in solute 
permeability in a tissue-engineered BBB model 
To study the mechanisms of hyperosmotic BBBO, we introduced mannitol into a tissue-engineered 
model of the BBB with a single 1 cm long microvessel that mimics the dimensions (~ 150 µm 
diameter) and wall shear stress (4 dyne cm-2) of a post-capillary venule (Figure 3-4, A-B) [181].   
Two days after seeding stem cell-derived human BMECs into genipin-crosslinked collagen 
channels (day 0), the formation of a confluent monolayer (Figure 3-4, C) results in physiological 
barrier function, as previously reported [198].  Microvessels were perfused with mannitol and the 
tracer fluorescein for 2 or 5 minutes.   Following dosing, the microvessels were then perfused with 
the fluorescent probes Lucifer yellow and 10 kDa dextran (Figure 3-4, D-E).  During this process, 
phase contrast microscopy was used to monitor the status of the endothelium, and epifluorescence 











Figure 3-4. Three-dimensional human in vitro model of hyperosmotic BBB opening. (a) 
Schematic illustrations of tissue-engineered iPSC-derived BBB microvessels including: (i) side 
view, (ii) front view, and (iii) three-dimensional view.  (b) Microvessels are continually perfused 
at ~4 dyne cm-2 shear stress via gravity-driven flow reservoirs.  (c) Phase contrast images of 










(d) Experimental timeline over four days.  (e) Imaging protocol for studying human BBB opening.   
Mannitol and fluorescein are added to the upper reservoir for two, five or ten minutes. Next Lucifer 
yellow and 10 kDa dextran are added to the upper reservoir for two hours.  Fluorescein is re-
administered for another hour.  (f) Timelapse images of: (i) phase, (ii) fluorescein, (iii) Lucifer 
yellow, and (iv) 10 kDa dextran are shown for a representative microvessel dosed with 1.4 M 
mannitol for five minutes.  (g-h) Representative fluorescence images of fluorescein during 2-minute 
and 5-minute mannitol doses.  Fluorescein focal leaks are widely observed during 5-minute 
exposure.  White arrows denote the sites of focal leaks. 
 
lumen and into the surrounding matrix (shown for a representative 5-minute mannitol dose in 
Figure 3-4, F). 
Fluorescein provides a proxy for the time-dependent concentration of mannitol in the microvessel 
and enables visualization of BBBO during and immediately after (~10 minutes) mannitol dosing.  
Fluorescein focal leaks develop during dosing, indicating that BBBO occurs rapidly following 
exposure to mannitol.  The densities of focal leaks during dosing were 0.24 ± 0.54 cm-1 and 5.59 ± 
4.35 cm-1 for 2-minute and 5-minute mannitol doses, respectively (Figure 3-5). 
 
Figure 3-5. Fluorescein tracing of BBB microvessels. (a) Time course of fluorescein fluorescence 
for representative 5-minute mannitol microvessel.  Fluorescein fluorescence peaks during mannitol 
dosing. Re-administration of fluorescein is used to monitor short-term recovery of barrier function.  
(b) Fluorescein focal leaks (n = 5 for each mannitol dose).  Only 5-minute mannitol exposure results 
in robust focal leak formation.  (c) Fluorescein focal leaks after redoing two hours later (n = 4 for 
each mannitol dose).  100% of 2-minute and 75% of 5-minute mannitol exposures displayed no 












Following dosing with mannitol, Lucifer yellow (MW 444 Da) and 10 kDa dextran were introduced 
into the microvessel to assess barrier function over the subsequent two hours.  Mannitol induces 
dose-dependent changes in permeability (Figure 3-6, A-B).  To assess the spatial heterogeneity in 
Lucifer yellow leakage, we determined the permeabilities in five adjacent segments (820 µm in 
width) along the length of the microvessels over 2 hours after dosing with mannitol (Figure 3-6, 
C).   Under baseline conditions (no mannitol), the Lucifer yellow permeability along the length of 
the microvessel varies by less than 68% between five adjacent ROIs.  In contrast, there is substantial 
spatial variation in Lucifer yellow permeability following 2- and 5-minute mannitol doses (on 
average 228%).  This variation is due to the appearance of focal leaks in different segments.  The 
minimum Lucifer yellow permeability across ROIs was 1.59 ± 0.87 x 10-7 cm s-1 (control), 8.27 ± 
8.66 x 10-7 cm s-1 (2-minute mannitol), and 28.8 ± 18.4 x 10-7 cm s-1 (5-minute mannitol).  5-minute 
mannitol doses result in significantly higher Lucifer yellow permeability compared to the control 
and 2-minute mannitol (p = 0.004 and p = 0.033, respectively) (Figure 3-6, D).  The maximum 
Lucifer yellow segment permeability (5-minute dose) was about 8 x 10-6 cm s-1, 50-fold higher than 
the average baseline permeability (control).  This increase in permeability represents the upper limit 
for transiently enhancing drug delivery.  Additionally, mannitol dosing resulted in increased 
variation in the Lucifer yellow permeability, with a 10-fold higher standard deviation compared to 
the controls.   
Increases in Lucifer yellow permeability result from discrete disruptions in barrier function at sites 
of focal leaks.  From analysis of 10 kDa dextran images, we found that focal leaks were located 
randomly across the entire length of microvessels (Figure 3-6, E).  Over the two-hour imaging 
period immediately after mannitol dosing, control microvessels displayed no focal leaks, 2-minute 
mannitol microvessels displayed ~3 focal leaks cm-1, and 5-minute mannitol microvessels 











Figure 3-6. Spatially heterogeneous dose-dependent hyperosmotic BBB 
opening.Representative images at 30, 60, and 90 minutes for (a) 10 kDa dextran and (b) Lucifer 
yellow under baseline conditions (no mannitol; control) or after 2-minute or 5-minute bolus doses 
of 1.4 M mannitol.  White arrows denote sites of focal leaks.  The onset of the mannitol dose begins 
approximately 2 minutes after injection into the reservoir.  Following the mannitol dose, the 
microvessels are perfused with Lucifer yellow and 10 kDa dextran for 2 hours. (c) The spatial 
dependence of Lucifer yellow permeability along microvessels (ROI = 825 µm segment) is highly 
heterogeneous following mannitol exposure. (d) Minimum Lucifer yellow permeability (i.e. the 
segment with the lowest permeability) for each condition. (e) Focal leaks are uniformly distributed 
along the length of the microvessels. (f) Focal leak density for each condition.  (g) Cumulative 10 
kDa dextran focal leaks and (h) normalized cumulative and instantaneous 10 kDa dextran 
extravasation following a 5-minute mannitol dose.  The dotted line represents the mean, while 
upper and lower solid lines represent the mean ± SD; time is normalized to onset of mannitol dosing 
at t = 2 minutes.  Control (n = 6 microvessels), 2-minute mannitol dose (n = 5 microvessels), and 











To determine the time course of BBBO, the number of 10 kDa dextran focal leaks and the 
penetration of the dye into the matrix were analyzed as a function of time (Figure 3-6, G-H).  New 
focal leaks are not observed after ~60 minutes following onset of a 5-minute mannitol dose.  
Additionally, extravasation of 10 kDa dextran occurs rapidly; half of all extravasation occurs within 
30 minutes following onset of mannitol administration, while no extravasation is observed in 
control microvessels, as previously reported [181]. 
To assess microvessel recovery, fluorescein was re-administered after the initial two-hour imaging 
window for an additional hour.  For 2-minute mannitol doses, fluorescein focal leaks were rare 
during dosing (0.24 ± 0.54 cm-1) and none were observed during fluorescein re-administration 
(Figure 3-5, C-D), indicating that BBBO is reversed and normal barrier function is re-established.  
For a 5-minute mannitol dose, while fluorescein focal leaks were observed (5.59 ± 4.35 cm-1) during 
initial dosing, two hours later focal leaks were rare (0.91 ± 1.82 cm-1 over 1 hour) and not observed 
in most microvessels (75%) (Figure 3-5, C-D).  After fluorescein re-administration only 4% of all 
focal leaks observed during 10 kDa dextran perfusion displayed persistent opening, indicating 
general reversal of BBBO within two hours of dosing.   
3.3.3.Endothelium response to mannitol dosing 
From phase contrast images, mannitol dosing induced morphological changes including BMEC 
shrinkage, thinning of the endothelium, and vacuolation.  Upon mannitol dosing, vacuoles formed 
in the dhBMECs (Figure 3-8, A); their density increased rapidly following the onset of mannitol 
dosing and reached a plateau thirty minutes later (Figure 3-8, B).  The formation of vacuoles was 
dose-dependent; 2-minute doses resulted in 6.7 ± 2.1 cell-1, while 5-minute doses resulted in 
significantly higher vacuolation of 10.6 ± 1.9 cell-1 (p = 0.005) (Figure 3-8, C).  Vacuoles were 3.8 
± 1.5 μm in diameter within microvessels exposed to 5-minute mannitol (Figure 3-7, C), excluding 










To gain insight into vacuole localization, microvessels were stained with Calcein AM and DAPI.  
Interestingly, the cytoplasmic stain Calcien AM was found to distinguish cytoplasm and nucleus 
from vacuoles.  Vacuoles were distributed heterogeneously within dhBMECs including within cell 
nuclei, within the cytoplasm, or at the boundary of cell nuclei (Figure 3-7, D).  Additionally, BMEC 
nuclei appeared distorted following mannitol treatment, likely due to abrupt changes in cell shape 
which alters nuclear shape via the actin cytoskeleton [303]. 
 
 
Figure 3-7. Vacuole quantification and characterization. (a) Vacuoles appear as white circles 
using phase contrast imaging, and are distinct from cytoplasm when stained with Calcein AM.  
Similar vacuole localization and counts are observed across both methods (representative images 
shown).  (b) Longitudinal analysis of vacuoles for a sample from each condition (x-axis represents 
> 6 mm).  There is not substantial variation in vacuole density along the length of microvessels.  
(c)  Probability distribution of vacuole diameter for 5-minute mannitol exposed microvessels (n = 
1127 vacuoles across n = 5 microvessels).  The mean vacuole diameter is ~4 μm.  (d) Calcein AM 
and DAPI stains of mannitol-exposed microvessels: vacuoles are not stained with Calcien AM, 
vacuoles localize internuclear (#1), extranuclear (#2) and in contact with both nucleus and 
cytoplasm (#3).  (e) DAPI and pHrodo Green AM stains of microvessels show that intracellular pH 











Vacuole formation could occur via multiple mechanisms.  Dextran remained excluded from 
intracellular compartments during and after mannitol dosing (Figure 3-8, D-E), indicating that 
vacuoles did not form as plasma membrane invaginations.  Dextran did not accumulate within the 
cytoplasm or vacuoles in the BMECs at any point during our experiments, implying that mannitol 
induces changes in paracellular permeability but not transcellular permeability for compounds with 
similar or higher molecular weight.  To further confirm that mannitol does not induce changes in 
membrane integrity, microvessels were stained before, or 30 minutes after, a 5-minute mannitol 
dose.  Most BMECs remained viable following mannitol treatment (Calcein AM), and although 
ethidium homodimer-1 positive cells were slightly more prevalent this was an exceedingly small 
population (~0.06 %) (Figure 3-8, F-G).  Next, we hypothesized that intracellular vacuoles were 
formed in response to an increase in hydrogen ion concentration (decrease in pH) resulting from 
the rapid loss of water.  However, there was no change in intensity or localization of a pH indicator 
dye (Figure 3-7, E).  The dye was co-localized with DAPI, suggesting that nuclei are the most 
acidic cell compartment under baseline conditions.   However, it is difficult to definitively conclude 
that vacuoles do not have a lower pH as indicator dyes could be restricted from entry into vacuoles, 
cleaved in the cytoplasm, or self-quenched at high concentrations.  Vacuoles have been observed 
in vivo following mannitol treatment, but were not correlated with BBBO [224]. 
Vacuole formation reduced the definition of dhBMECs in phase contrast imaging, making it 
difficult to measure cell loss events [181].  However, from timelapse imaging at the microvessel 
midplane, loss of dhBMECs from the endothelium is observed following mannitol dosing.  Cell 
loss is dose-dependent, with events observed ~6 or ~2 times more frequently following 5-minute 
doses, compared to control and 2-minute doses, respectively (Figure 3-8, I).  Increased apoptosis 











Figure 3-8. Hyperosmotic vacuole formation and tight junction disruption in BBB 
microvessels.Vacuolation of endothelial cells is dose-dependent: (a) representative time course 
images of bottom plane of microvessel upon exposure to mannitol.  t = 0 minutes represents 
addition of Lucifer yellow and 10 kDa dextran to the upper reservoir, after which the onset of 
mannitol dose occurred eight or six minutes later for the 2-minute or 5-minute mannitol doses 
shown, respectively.  Red arrows denote examples of vacuoles visible from phase contrast 
microscopy.  (b) Time course of vacuole formation, (c) maximum vacuoles across doses.  (d-e) 10 
kDa dextran does not accumulate intracellularly following mannitol exposure: (d) representative 
10 kDa dextran and phase contrast images, (e) intensity projection of 10 kDa dextran along the 
dashed white line in subsequent subpanel. (f-g) Live-dead stains (Calcien AM, ethidium 
homodimer-1) and percentage of ethidium homodimer-1 positive cells before and after mannitol 
exposure (n = 3 microvessels).  (h) Cumulative cell loss over two hours for each condition.  (i) 
Confocal imaging at the midplane of a microvessel following a 5-minute mannitol dose shows a 










endothelium is intact showing that the focal leak has closed.  (j) Epifluorescence image of a 10 kDa 
dextran focal leak at the midplane of a microvessel following a 5-minute mannitol dose.  Concurrent 
epifluorescence imaging of tight junctions (ZO1) shows no global changes in TJ localization during 
hyperosmotic BBB opening.  For quantification of vacuoles and cell loss: control (n = 6 
microvessels), 2-minute mannitol dose (n = 5 microvessels), and 5-minute mannitol dose (n = 5 




Figure 3-9. Confocal tracing of focal leaks during hyperosmotic BBB opening (5-minute 
mannitol dose). (a)  Focal leaks are visible as a pathway of fluorescence from lumen to ECM that 
is restricted to a specific z-plane.  20 μm above or below this plane BMECs do not display 
accumulation of 10 kDa dextran or other obvious disruptions.  (b) Time lapse imaging during (open; 
t = 20 min) and after (closed; t = 70 minutes) focal leakage.  (c) Fluorescence intensity along 
projections of the y- and x-axis, respectively (dashed white lines).  Open focal leaks display 
elevated 10 kDa dextran fluorescence at the plane of the endothelium. 
 
3.3.4.Characterization of focal leaks 
Confocal images during perfusion with 10 kDa dextran shown that the focal leaks are associated 
with small gaps (1 – 2 µm) in the endothelium (Figure 3-8, I).  Images above and below the z-plane 
(0.4 μm thickness) show no leakage (Figure 3-9). There is no evidence of intracellular accumulation 










from exclusion of 10 kDa dextran from the endothelium 50 minutes later.    
To further investigate the mechanism of tight junction disruption, we performed live-cell imaging 
of BBB microvessels where the dhBMECs were differentiated from iPSCs with fluorescently 
labeled zona occludens-1 (ZO1).  Following mannitol administration the global tight junction 
structure is not perturbed (Figure 3-8, J).  Direct visualization of TJ disruption at the site of a focal 
leak is not possible due to limited z-resolution at the microvessel midplane where the focal leaks 
are visualized.  However, from analysis of the images at the top and bottom of the microvessels, 
we can show that there is no disruption in ZO1 within about 125 μm (~5 cell lengths) of a focal 
leak (Figure 3-10).  
 
Figure 3-10. Confocal tracing of focal leaks and tight junctions during hyperosmotic BBB 
opening. (a) 5-minute mannitol doses result in focal leaks visible by 10 kDa dextran leakage at the 
microvessel midplane.  (b)  Phase contrast and zona occludens-1 (ZO1) fluorescence images were 
acquired at the midplane and microvessel poles, during focal leakage.  Visualization of TJ 
disruption is challenging at the microvessel midplane, while at planes above and below the focal 
leak, tight junctions appear intact and well-localized.   
 
 
3.3.5.bFGF pre-treatment attenuates BBB opening 
To assess the role of bFGF in modulating BBB function, microvessels were treated with 20 ng mL-










mannitol) pre-treated with bFGF displayed similar Lucifer yellow permeability on day 0 compared 
to control microvessels (p = 0.449), although there was an increase in the number of vacuoles (p = 
0.003) (Figure 3-11, B).  Pre-treatment with bFGF increases the transendothelial electrical 
resistance (TEER) of iPSC-derived BMEC monolayers within 2D transwells (p = 0.021, Figure 
3-12, A).  However, increased TEER was not associated with increases in endothelial cell density 
(p = 0.750), total tight junction fluorescence intensity (p = 0.755), or junctional localization (Figure 
3-12, B-D).  Microvessels pre-treated with bFGF and then exposed to a 5-minute mannitol dose 
(on day 0) were less susceptible to BBBO (Figure 3-11, C).  The minimum Lucifer yellow 
permeability and the presence of focal leaks were reduced with bFGF pre-treatment (p = 0.029 and 
0.036, respectively) compared to control microvessels (Figure 3-11, D).  For example, following a 
5-minute mannitol dose, the minimum permeability was 3.02 ± 2.14 x 10-7 cm s-1, 10-fold lower 
than with no bFGF treatment.  Similarly, the number of focal leaks decreased from 18 ± 12 cm-1 to 
1.8 ± 1.6 cm-1 following pre-treatment with bFGF.   The maximum number of vacuoles per cell 
was slightly higher with bFGF pre-treatment, although not statistically significant (p = 0.113) 
(Figure 3-11, D).   
However, microvessels pretreated with bFGF and exposed to a 10-minute mannitol dose displayed 
BBBO (Figure 3-13).The minimum Lucifer yellow permeability was higher than bFGF-pretreated 
microvessels not exposed to mannitol (p = 0.0459), and similar to that of 2-minute mannitol doses 
in control microvessels; both displayed an average minimum Lucifer yellow permeability of 
approximately 7 - 8 x 10-7 cm s-1, about 5-fold higher than the control.   10 kDa dextran focal leaks 
were observed with 10-minute mannitol dose (9.3 ± 8.3 cm-1), although not significantly greater 
than controls (no bFGF).  The concentration of vacuoles increased compared to controls (p = 
0.0002) but was similar to those observed with 5-minute mannitol treatment, suggesting that 












Figure 3-11. Basic fibroblast growth factor (bFGF) pre-treatment mitigates BBB opening. (a) 
Summary of 20 ng mL-1 bFGF treatment.  (b) Comparison of the minimum Lucifer yellow 
permeability, the number of focal leaks, and the number of vacuoles following a 5-minute mannitol 
dose with (n = 3) and without bFGF pre-treatment with (n = 6).  (c) Representative images of 10 
kDa dextran and Lucifer yellow in bFGF pre-treated microvessels following a 5-minute mannitol 
dose showing no focal leaks.  (d) Comparison of the minimum Lucifer yellow permeability, the 
number of focal leaks, and the number of vacuoles following a 5-minute mannitol dose with (n = 




Figure 3-12. Influence of bFGF pre- and post-treatment. (a) Basic fibroblast growth factor 
(bFGF) pre-treatment increased transendothelial electrical resistance (TEER) of dhBMEC 
monolayers in a transwell on day 0, in the absence of mannitol dosing (n = 5).  (b) bFGF pre-
treatment had no effect on cell density (n = 4).  (c) Analysis of zona occludens-1 and claudin-5 in 
immunofluorescence images showed no effect on junction intensity in immunofluorescence images 
(n = 4).  (d) Immunofluorescence images of zona occludens-1 and claudin-5 in two-dimensional 
monolayers on day 0 display no clear difference with and without bFGF pre-treatment.  (e) Cell 
density obtained from analysis of phase contrast images of microvessels 2 days following a 5-
minute mannitol dose (n = 3).  bFGF post-treatment (continuous perfusion beginning 2 hours 











Figure 3-13. Basic fibroblast growth factor (bFGF) pre-treatment mitigates BBB opening, 
requiring a longer dose to induce opening. (a) Representative images of 10 kDa dextran and 
Lucifer yellow in bFGF pre-treated microvessels exposed to 10-minute mannitol, focal leaks are 
denoted with white arrows.  (b) Comparison of minimum Lucifer yellow permeability, focal leaks 
and vacuoles between microvessels pre-treated with bFGF exposed to no mannitol (n = 3) or 10-
minute mannitol (n = 3).  (c) Representative images of 10 kDa dextran and Lucifer yellow in bFGF 
pre-treated microvessels exposed to 10-minute mannitol 48 hours after mannitol exposure (day 2), 
focal leaks are not observed.  (d) Comparison of minimum Lucifer yellow permeability, focal leaks 
and vacuoles between microvessels pre-treated with bFGF exposed to no mannitol (n = 3) or 10-




and exposed to 10-minute mannitol doses returned to baseline levels within 48 hours (by day 2).  
On day 2, the minimum Lucifer yellow permeability, the number of focal leaks, and the vacuole 
density were indistinguishable from baseline bFGF pre-treated microvessels (p > 0.05).   
3.3.6.bFGF post-treatment enhances BBB stability 48 hours after mannitol dosing 
Endogenous bFGF circulates in human blood at concentrations in serum below ~10 pg mL-1 [306].  
To aid in recovery and repair following injuries, administration of exogenous bFGF or other growth 
factors has been explored [307-310].  Treatment with hyperosmotic agents perturbs endothelial 
homeostasis and causes significant stress to BMECs.  Previously, we showed that focal leaks two 










To investigate the long-term response to mannitol stress, we investigated barrier function 48 hours 
following treatment with and without bFGF continuously administered starting 2 hours after 
mannitol dosing (Figure 3-14, A).  Without bFGF post-treatment, BBB microvessels displayed 
variable barrier function 48 hours following a 5-minute mannitol dose (Figure 3-14, B).  The 
minimum Lucifer yellow permeability decreased 48 hours following dosing (day 2) and was 
approximately three times higher than the baseline control although not statistically significant (p 
= 0.360) (Figure 3-14, C).  While widespread disruption of the monolayer was not observed 48 
hours following dosing, some microvessels did display leakage of 10 kDa dextran indicating 
instability of barrier function (Figure 3-14, D).  With bFGF post-treatment, all microvessels 
displayed stable barrier function following hyperosmotic BBBO (Figure 3-14, F).  The minimum 
Lucifer yellow permeability 48 hours following 5-minute mannitol dosing was 3.42 ± 1.74 x 10-7 
cm s-1, approaching physiological values, and similar to controls (no mannitol, no bFGF) (p = 
0.132) (Figure 3-14, G).  In addition, with bFGF post-treatment no focal leaks were observed, 
representing a significant decrease from the response immediately after mannitol dosing (p = 0.047) 
(Figure 3-14, H).  The recovery of dhBMEC vacuolation was not dependent on bFGF post-
treatment; under both conditions vacuolation decreased by ~10-fold 48 hours following 5-minute 
mannitol dosing (p = 0.007 and 0.013, for control and bFGF post-treatment microvessels 
respectively) (Figure 3-14, E, I).   Administration of bFGF after mannitol dosing was associated 
with a small, non-significant increase in cell density, possibility due to increased BMEC 











Figure 3-14. bFGF post-treatment promotes BBB repair following hyperosmotic opening. (a) 
Microvessels were continuously perfused with 20 ng mL-1 bFGF following a 5-minute mannitol 
dose.  (b) Representative images of 10 kDa dextran and Lucifer yellow on day 2 following a 5-
minute mannitol.  Focal leaks are denoted by white arrows.  (c-e) Comparison of minimum Lucifer 
yellow permeability, the number of focal leaks, and the number of vacuoles after a 5-minute 
mannitol dose, and on day 2 following dosing (n = 3).   (f) Representative images of 10 kDa dextran 
and Lucifer yellow on day 2 following a 5-minute mannitol dose in bFGF post-treated microvessels.  
No focal leaks are observed.  (g-i) Comparison of minimum Lucifer yellow, the number of focal 
leaks, and the number of vacuoles after a 5-minute mannitol dose, and on day 2 following dosing 




MRI assessment of BBB status in animal models does not provide sufficient spatial resolution for 
studying the mechanisms of BBBO.  Here, we utilize time lapse imaging to visualize hyperosmotic 
BBBO in a tissue-engineered microvessel model with human stem cell-derived BMECs [181, 198].  
In the current model for transient hyperosmotic BBBO, removal of water induces vasodilation, and 
above a critical threshold (related to the product of osmolarity and injection duration), vasodilation 










287, 288].  This model usually assumes a time-dependent but spatially homogeneous increase in 
permeability [259].  
3.4.1.Mannitol induces spatially heterogeneous increases in paracellular permeability  
The key observations from imaging mannitol-induced BBBO in microvessels are: (1) mannitol 
causes transient focal leaks that result in a significant increase in the overall permeability, (2) the 
focal leaks occur at small (1 – 2 µm) sub-cellular disruptions in the endothelium, (3) the global TJ 
network is unaffected by mannitol, and (4) the increase in permeability is due solely to paracellular 
transport.  Together these results suggest that focal leaks are formed by disruption of TJs between 
adjacent cells. 
A 1 cm long, 150 μm diameter microvessel consists of ~8,000 cells (average cell area is 625 μm2), 
with each cell having ~6 neighbors [181], corresponding to a total of 48,000 unique cell-cell 
junctions.  Therefore, the observation of 18 focal leaks (assuming that focal leaks occur when a 
single cell-cell junction is disrupted) in response to a 5-minute mannitol dose corresponds to a 
failure of 0.04% of TJs or ~0.25% of all dhBMECs.  This suggests that there is a distribution of TJ 
strengths and it is the weakest TJs that are the first to be disrupted during mannitol dosing.  
Consistent with this hypothesis, spatial heterogeneity in endothelial barrier function was reported 
in 2D monolayers in response to histamine treatment utilizing total internal reflection fluorescence 
(TIRF) microscopy [311]. 
Under baseline conditions, the permeability of 10 kDa dextran is below the detection limit and there 
is no appreciable intracellular accumulation indicating negligible paracellular and transcellular 
transport.  Following mannitol dosing, the permeability of 10 kDa dextran increases via focal leaks 
but there is no intracellular accumulation or widespread BMEC membrane permeabilization (i.e. 
low ethidium homodimer-1 fraction), consistent with negligible transcellular transport.   Despite 










the minimum Lucifer yellow segment permeability increases 20-fold over 20 minutes following a 
5-minute mannitol dose.  This increase matches previous measurements of baseline Lucifer yellow 
permeability within human umbilical vein endothelial cell microvessels (~4 x 10-6 cm s-1) [181].  
These results suggest that transient BBBO following mannitol dosing is associated with a small 
number of focal leaks that are responsible for rapid extravasation of solutes into the surrounding 
matrix.  We note that mechanisms of BBBO and response to mannitol may be different in other 
conditions, such as trauma and stroke [1, 312, 313]. 
3.4.2.Timeline of hyperosmotic BBB opening, drug delivery and recovery 
To further elucidate the timeline of opening and recovery, we normalized experimental metrics to 
the onset of a 5-minute mannitol dose (Figure 3-16).  Fluorescein focal leaks appear during 
mannitol dosing, suggesting that changes in BBB permeability can occur almost instantaneously, 
matching observations from dynamic T1 MRI.  The emergence of dhBMEC vacuolation and the 
decrease in microvessel diameter show delayed responses compared to focal leaks, with half-times 
of 6.5 and 12 minutes, respectively, after dose onset.  This suggests that vacuolation and changes 
in microvessel diameter are not direct mediators of BBBO. 
Drug delivery, based on extravasation of 10 kDa dextran, is proportional to focal leak density and 
persistence.  The cumulative number of focal leaks for 5-minute mannitol doses display a half-time 
of 20 minutes after dose onset.   The extravasation of 10 kDa dextran occurs over a longer period 
(τ = 30 minutes), due to the persistence of focal leaks.  The persistence of focal leaks following a 
5-minute mannitol dose spanned an order of magnitude, from less than 2 minutes to more than 20 
minutes (Figure 3-15).  Determining the persistence time was complicated due to impingement of 
dextran from neighboring focal leaks.  Cell loss is significantly delayed from the onset of focal 
leaks and leakage of fluorescent probes into the matrix (τ = 60 minutes), supporting the hypothesis 












Figure 3-15. Mechanisms of hyperosmotic BBB opening, drug delivery, and recovery.Cross-
sectional view of BBB microvessels during and after mannitol dosing, with (b) zoom-in on tight 
junctions (TJs) between adjacent BMECs.  (c) Mechanistic timeline: fluorescein focal leaks first 
emerge during dosing followed by vacuoles and 10 kDa dextran focal leaks after dosing.  Drug 
delivery is proportional to focal leak density and persistence.  Short-term recovery is visible as 
cessation of fluorescein focal leaks, while in the long-term mannitol can compromise stability.  TJ 
strengthening (bFGF pre-treatment) mitigates BBB opening, while BMEC proliferation (bFGF 
post-treatment) promotes BBB opening.  (d) Time course of events over the initial 20 minutes of 
imaging and (e) over two hours of imaging following a 5-minute mannitol dose (n = 5 
microvessels).  All events are normalized to the 5-minute dose in which fluorescein fluorescence 
peaks, corresponding to the vertical grey bar from 2 to 7 minutes.  Half-times (τ) are reported with 
respect to onset of dose (t = 2 minutes).  The dotted line represents the mean, while upper and lower 











(Figure 3 16, E).  Over two hours following a 5-minute dose ~2% of all BMECs are lost from the 
microvessel, likely due to induced apoptosis from hyperosmotic stress [301, 302].10 kDa dextran 
extravasation into the ECM (a proxy for drug delivery into the brain) is dramatically increased by 
mannitol dosing.  In contrast, in the absence of mannitol dosing, there is no detectable leakage of 
dextran from the microvessel.  Techniques to modulate transcellular permeability, including efflux 
pump inhibition, have a more modest potential to alter CNS drug penetration. For example, p-
glycoprotein inhibition in vivo [252] and in vitro [181] modulates efflux pump substrate 
permeability by only 2- to 3-fold.  Thus, hyperosmotic methods for BBBO have a distinct advantage 
for delivery of large molecular weight compounds that are not efflux substrates. 
 
 
Figure 3-16. Persistence of 10 kDa dextran focal leaks. (a) For a representative 5-minute 
mannitol exposed microvessel, focal leaks of various persistence are shown.  White arrows denote 
an active focal leak characterized by increasing extravascular fluorescence.  (b) Normalized 
extravascular fluorescence (within the dotted ROI drawn in sub-panel a) is plotted over 30 minutes.  
Duration of extravascular fluorescence increase corresponds to focal leaks of short, medium and 
long persistence.  t = 0 minutes represents addition of Lucifer yellow and 10 kDa dextran to the 
upper reservoir, after which the onset of mannitol dose occurred two minutes later for the 5-minute 











Based on the time-dependent responses, we propose that mannitol induces shrinkage of BMECs 
which increases the tensile stress on TJs (Figure 3-16, Figure 3-17).  Cell shrinkage continues to a 
point where TJs between adjacent cells are compromised.  Assuming a distribution of TJ strength, 
the weakest TJs fail first resulting in transient focal leaks and a local increase in paracellular 
permeability.  Microvessels exposed to low doses of mannitol do not reliably open due to 
insufficient cell volume loss, while bFGF pre-treatment strengthens TJs preventing BBBO.  Long 
term failure of barrier function is likely due to accumulated hyperosmotic stress on BMECs, which 
can be recovered by promoting cell proliferation with bFGF post-treatment.  
 
 
Figure 3-17. Proposed mechanism of hyperosmotic BBB opening, drug delivery, and 
recovery.Mannitol induces cell shrinkage which increases tensile stress on tight junctions (TJs).  
Opening occurs as a function of the magnitude of cell shrinkage and TJ strength (i.e. insufficient 
cell volume loss or strengthened TJs prevent BBB opening).  Paracellular permeability increases 
due to focal leakage at the site of TJ disruption.  Once TJs are re-established, barrier integrity is 
resumed. 
  
3.4.3.Baseline permeability is not a predictor of susceptibility to BBB opening  
Pre-treatment with bFGF does not alter baseline permeability of microvessels but does increases 
the mannitol dose required to induce BBBO.  This suggests that bFGF shifts the distribution of TJ 
strengths so that longer doses are required to exert sufficient stress on the weakest TJs to initiate 
opening.  In the context of the brain, it is possible that some regions are more resistant to opening 










of location.  For example, the cerebral cortex does not exhibit significant BBBO following 
hyperosmotic therapy in mice [295].  It is not well understood if this is due to heterogeneity of TJ 
strength [230] or hemodynamics and the mannitol distribution compared to other brain regions.  In 
vitro, treatment with bFGF upregulates primary hBMECs TJ proteins [308].  Additionally, while 
bFGF is not required to achieve physiological barrier function (low permeability), as shown here 
and previously [181], its removal during seeding of transwells with dhBMECs reduces 
transendothelial electrical resistance (TEER).  Thus, bFGF is likely able to shift the distribution of 
TJ strengths so that a 10-minute mannitol dose is required to induce disruption.  Importantly, these 
results imply that the culture conditions of in vitro BBB models impact interpretation of BBBO 
efficacy.  
3.4.4.Long-term recovery to BBB opening is promoted by bFGF 
Fluorescein focal leaks were not observed two hours after a 2-minute mannitol dose and were 
uncommon (25% of microvessels) following a 5-minute dose, indicating that barrier function has 
largely recovered within two hours.  However, the hyperosmotic stress on dhBMECs resulted in 
inconsistent barrier function 48 hours following dosing in the absence of exogenous growth factors.  
Focal leaks and increased permeabilities were observed 48 hours after 5-minute mannitol doses.  In 
previous work, BBB microvessels not exposed to mannitol displayed no focal leaks and stable 
permeability over six days after seeding [181].  Post-treatment of microvessels with bFGF 
promoted recovery from hyperosmotic stress in the 48 hours following dosing.  A possible 
explanation for the influence of bFGF is that it promotes cell growth, and increases cell density, 
thereby reducing the stress on the dhBMECs in response to hyperosmotic stress.   Although, we 
measure a small increase in cell density, it is not significant (p = 0.326, Figure 3-12, E).  However, 










In vivo studies of the duration of osmotic BBBO have reported conflicting timelines [265, 294, 
314].  These inconsistencies likely result from differences in species, anesthetic agents, infusion 
rates, doses, tracers, and imaging techniques, among other factors.  Across 38 human subjects, 
good-to-excellent BBB disruption was obtained in ~75% of patients, while the remaining 25% 
displayed poor-to-moderate disruption [294]. This study reported that the BBB remained open for 
at least 40 minutes after osmotic exposure and returned to baseline after six to eight hours following 
induction of good-to-excellent BBBO [294].  We find that BBBO is generally reversible within 
two hours.  Additionally, our results suggest that mannitol treatment induces stress in dhBMECs 
that, for larger doses, manifests two days later as disruptions in barrier function, but which can be 
recovered by bFGF treatment.  bFGF exerts a protective effect on BBB damage following traumatic 
brain injury and intracerebral hemorrhage in mice [308, 309].  While bFGF treatment is not required 
to reverse hyperosmotic therapies in vivo, supporting cells (i.e. pericytes [315] or astrocytes [316]) 
may play a role in recovery.    
3.4.5.Model advantages and limitations 
Our tissue-engineered microvessel model mimics key components of the human BBB, including 
physiological permeability, cylindrical geometry, cell-matrix interactions, and shear stress.[26]  
Microvessels formed from dhBMECs exhibit low permeability of small molecules, consistent with 
physiological BBB function in animal models [225, 317].  Previous in vitro studies have relied on 
modeling hyperosmotic BBBO within two-dimensional microfluidic systems [318] or hollow-fiber 
based platforms [267, 319], where direct visualization of cell behavior is challenging.  There are 
two main limitations to our model for studying hyperosmotic BBBO.  (1) Microvessels are 
comprised of only BMECs.  Recent evidence suggests that other cellular components of the BBB 
are not necessary to maintain physiological permeability in vitro [26, 320], but may play a critical 










(2) Microvessels mimic features of brain post-capillary venules but are larger than brain capillaries 
(typically 8 - 10 μm).  The influence of diameter on BBBO susceptibility is unknown.  These 
differences may explain discrepancies in mannitol doses required to initiate BBB opening.   
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4.1.Introduction 
Brain angiogenesis is a multistage process by which new capillaries sprout from existing blood 
vessels.  The culmination of brain angiogenesis during development results in a 600 km network 
of capillaries forming the blood-brain barrier (BBB) [4].  Brain microvascular endothelial cells 
(BMECs), which form the interface between the vascular system and the brain parenchyma, 
regulate transport into the brain via expression of tight junctions (TJs), efflux pumps, and nutrient 
transporters [6, 26].  The ability to study brain angiogenesis in vitro has been limited by a lack of 
3D models and an appropriate source of brain microvascular endothelial cells.  Consequently, 
previous studies have relied on two-dimensional assays such as the Matrigel tube assay and cord-
forming assays, or utilize primary / immortalized cells, which display an incomplete BBB 
phenotype [324-326].   
To enable imaging of angiogenesis in 3D, we have adapted the fibrin bead angiogenesis assay 










(dhBMECs) on microbeads (BBB beads).  The beads are then embedded in a collagen I hydrogel, 
which mimics the native stiffness of brain parenchyma [328].   We then explore how changes in 
the chemical and extracellular matrix microenvironment influence angiogenesis.  We report on the 
influence of pro-angiogenic cues including vascular endothelial growth factor (VEGF) [70], 
wnt7a/b [71], and basement membrane [329].  In addition, to mimic pathological angiogenesis in 
response to oxidative stress, we report on the dose-dependent effects of hydrogen peroxide.  
DhBMECs have emerged as an attractive cell source for BBB models as: (1) species differences 
mean that animal models do not always recapitulate human disease [185, 330], (2) reliable and 
diverse protocols have been developed to differentiate BMECs [194, 196, 197], and (3) patient-
specific and CRISPR gene-edited iPSCs are available for controlled studies on how genetic 
mutations impact cell phenotype [137, 331, 332].  Additionally, dhBMECs recapitulate key aspects 
of BBB phenotype including high transendothelial electrical resistance, restriction of paracellular 
permeability, and efflux activity [26] [333].  Primary and immortalized BMECs, which de-
differentiate during in vitro culture [334], are often deficient in these characteristics and are not 
easily scalable for isogenic or patient-specific studies [335]. 
We also apply our results from the BBB bead angiogenesis assay to improve design of tissue-
engineered hierarchical BBB models.  Existing 3D models of brain angiogenesis based on self-
organization approaches [180, 209, 336] fail to recapitulate the hierarchy of the human BBB, 
consisting of capillaries fed by an input arteriole and output venule.  Engineering hierarchal 
microvascular models is limited by the spatial and temporal resolution of current techniques [336-
339].  Our lab has demonstrated a hybrid approach relying on both templating and angiogenesis to 
form hierarchical microvascular networks using human umbilical vein endothelial cells (HUVECs) 
[340].  Here, after formation of microvessels resembling post-capillary venules (PCVs) by seeding 










promote sprouting and anastomosis between adjacent microvessel to recapitulate a key aspect of 
human BBB function, low solute permeability.  Our three-dimensional models provide a diverse 
toolbox for studies of brain angiogenesis.  
4.2.Materials and methods 
4.2.1.Cell culture 
Brain microvascular endothelial cells (BMECs) were differentiated from hiPSCs similar to 
published protocols [196, 300].  The WTC iPSC line [299] with red fluorescent protein-tagged 
plasma membrane (Allen Cell Institute) was used to facilitate live-cell monitoring of angiogenesis.  
WTC iPSCs were plated at 10,000 cells cm-2 on Matrigel-coated plates and grown for two days in 
mTESR1 (StemCell Technologies) to approximately 25% confluency, with 10 μM ROCK inhibitor 
Y27632 (RI; ATCC) supplemented for the initial 24 hours.  Subsequent six-day treatment with 
unconditioned media without bFGF (UM/F-): DMEM/F12 (Life Technologies) supplemented with 
20% knockout serum replacement (Life Technologies), 1% non-essential amino acids (Life 
Technologies), 0.5% GlutaMAX (Life Technologies) and 0.836 μM beta-mercaptoethanol (Life 
Technologies), and two-day treatment with RA media: human endothelial cell serum-free media 
(Life Technologies) supplemented with 1% human platelet poor derived serum (Sigma), 2 ng mL-
1 bFGF (R&D Systems), and 10 μM all-trans retinoic acid (RA; Sigma) produces dhBMECs.  
Differentiations were conducted over a ten-passage window on six-well plates using media 
volumes of 1 mL and daily media switches.  Transendothelial electrical resistance (TEER) 
measurements were used to confirm the quality of differentiations as previously reported [196]; the 
average TEER for WTC-RFP cells after 48 hours was ~2,500 Ω cm2.   
VeraVec HUVEC-TURBO-GFP cells (HUVECs; Angiocrine Bioscience) were used as a non-brain 
specific endothelial cell control.  HUVECs were grown in “HUVEC media”: MCDB 131 (Caisson) 










1 hydrocortisone (Sigma), 10 µg mL-1 heparin (Sigma), 25 µg mL-1 endothelial cell growth 
supplement (Thermo Fisher), and 0.2 mM ascorbic acid 2-phosphate (Sigma).  HUVECs were used 
until passage 7 and routinely passed using TrypLE Express (Life Technologies). 
4.2.2.Forming endothelial monolayers on microbeads  
Assay protocols were adapted from those developed for primary endothelial cells [327].  150 μm 
diameter Cytodex 3 microcarrier beads (GE Healthcare) were prepared according to 
manufacturer recommendations.   Beads were coated overnight with 50 μg mL-1 human placental 
collagen IV (Sigma) and 25 μg mL-1 fibronectin from human plasma (Sigma).  dhBMECs were 
singularized using 30 minute StemPro accutase (ThermoFisher) treatment and incubated at a ratio 
of 1000:1 (dhBMECs:beads) for two hours under gentle agitation every 30 minutes.  “Bead seeding 
media” was comprised of human endothelial cell serum-free media (Life Technologies) 
supplemented with 1% human platelet poor derived serum (Sigma), 1% Penicillin Streptomycin 
(Thermo Fisher), 2 ng mL-1 bFGF (R&D Systems), 10 μM all-trans retinoic acid (Sigma), and 10 
μM ROCK inhibitor Y27632 (RI).  Inclusion of RI was required to enable cell adhesion, as 
previously found for collagen-based biomaterials [198].  After two hours, non-adherent dhBMECs 
were removed and beads were cultured for 24 hours on a shaker at 100 rpm in bead seeding media.  
To form HUVEC coated beads, identical protocols were used with the following differences: (1) 
incubation with cells for only one hour, (2) use of HUVEC media without supplementation with 
RI. 
4.2.3.Immunocytochemistry 
After 24 hours on a shaker (day 1), beads were fixed and stained to assess protein expression.  Beads 
were rinsed with room-temperature phosphate-buffered saline (PBS; ThermoFisher) and then 
collected using brief centrifugation (30 seconds at 0.3 g).  Beads were fixed using ice-cold methanol 










Technology) and 0.3% Triton X-100 (Millipore Sigma), and then treated with primary antibodies 
diluted in blocking buffer overnight at 4 ˚C (Table 4-1).  After washing with PBS three times, cells 
were treated with 1:200 Alexa Flour-488 or Alexa Flour-647 secondary antibodies (Life 
Technologies) diluted in blocking buffer for 45 minutes at room temperature.  To physically 
constrain beads for confocal imaging and to stain cell nuclei, beads were loaded onto eight-
chambered borosilicate cover glass wells with Fluoromount-G with DAPI (Invitrogen).  Confocal 
images were acquired at 40x magnification on a swept field confocal microscope system (Prairie 
Technologies) with illumination provided by an MLC 400 monolithic laser combiner (Keysight 
Technologies).  As a negative control, beads were not exposed to primary antibodies to determine 
signal due to non-specific secondary antibody binding. To conduct immunocytochemistry of 
microvessels, antibodies and buffers were perfused through microvessel lumens with identical 
incubation times. 
Table 4-1. Antibodies used in this study. 
Antibody Vendor Species Cat. No Dilution 
Occludin Invitrogen Rabbit 40-4700 1:100 
Claudin-5 Invitrogen Mouse 35-2500 1:200 
GLUT1 Abcam Rabbit 115730 1:200 
P-gp Sigma Mouse P7965 1:100 
CD31 ThermoFisher Rabbit RB-10333 1:25 
FGFR2 R&D Mouse MAB684 1:100 
VEGFR2 R&D Mouse MAB3572 1:100 
GPR124 R&D Mouse MAB8896 1:100 
 
4.2.4.Permeability assay 
Beads were suspended in 200 μM Lucifer yellow (CH dilithium salt; LY) (Sigma) to confirm 
restriction of paracellular transport.  After three hours, confocal images were acquired at the bead 
midplane to determine accumulation of LY from the fluorescence within beads.  Three conditions 










LY.  A circular region of interest (ROI) within beads was used to compare normalized fluorescence 
intensity across conditions.  
4.2.5.Bead angiogenesis assay 
On day 1 (24 hours after seeding dhBMECs), beads were suspended into hydrogels at ~100 beads 
mL-1 and gelled in a 250 μL volume within eight-chambered borosilicate cover glass wells (Lab 
Tek).  Hydrogels were comprised of 6 mg mL-1 neutralized rat tail type I collagen (Corning).  After 
30 minutes of gelation, cell culture media was added on top of hydrogel and replenished daily.  
Both cell culture media and ECM conditions were toggled to optimize angiogenic growth.  Basal 
media consisted of human endothelial cell serum-free media (Life Technologies) supplemented 
with 1% human platelet poor derived serum (Sigma) and 1% Penicillin Streptomycin (Thermo 
Fisher).  Basal media was further supplemented with 20 ng mL-1 bFGF (R&D Systems), 50 ng mL-
1 recombinant human Wnt-7a (Wnt7a; Fisher Scientific), and 50 ng mL-1 recombinant human 
VEGF-165 (VEGF; Biolegend).  In some experiments, hydrogels were supplemented with 
additional ECM components, including 1.5 mg mL-1 growth factor reduced Matrigel (Corning), 1.5 
mg mL-1 fibrin, and 0.5 mg mL-1 fibronectin from human plasma.  Fibrin composite hydrogels were 
formed by combining 2 U mL-1 thrombin from bovine plasma (Sigma) with 6 mg mL-1 neutralized 
rat tail type I collagen (Corning), before addition of 1.5 mg mL-1 fibrinogen from bovine plasma 
(Sigma).  Across all experiments, media was replenished daily (250 μL volume).   
4.2.6.Imaging and analysis 
Phase contrast and epifluorescence images (Texas Red filter) of beads were acquired on an inverted 
microscope (Nikon Eclipse TiE) at 10x magnification.  For each experimental condition, ten images 
(technical replicates) of individual beads were collected at day 2, 4 and 6 after embedding in 
hydrogels.  Beads whose endothelium grew along the glass-collagen interface were excluded from 










greater than thickness. Three measures were calculated in ImageJ (NIH): (1) Angiogenic 
percentage (%), defined as the percentage of beads that display angiogenic sprouts, (2) sprout 
density (# bead-1), and (3) maximum sprout length (μm).  
4.2.7.Modeling oxidative stress 
Hydrogen peroxide (H2O2; Sigma) was prepared in water and then supplemented in media to final 
concentrations of 1 mM and 10 μM.  Vehicle treatment consisted of 1% water.  H2O2 was added 
after embedding beads in hydrogels and was included in daily media switches.  All oxidative stress 
experiments were conducted in 6 mg mL-1 rat tail type I collagen and 1.5 mg mL-1 Matrigel, treated 
with basal media for 6 days.   
4.2.8.Microvessel fabrication 
Three-dimensional BBB microvessels were fabricated as previously reported  [300].  Briefly, 1 cm 
(length) x 1.75 mm (width) x 1 mm (height) channels were cast in polydimethylsiloxane (PDMS; 
Dow Corning) using an aluminum mold.  Neutralized 6 mg mL-1 rat tail type I collagen 
supplemented with 1.5 mg mL-1 Matrigel was gelled surrounding a template 150 μm diameter 
super-elastic nitinol wire (Malin Co.).  After 30 minutes at 37 ˚C, template wires were removed to 
leave behind a channel that was subsequently seeded with singularized dhBMECs.  Microvessels 
were perfused under ~2 dyne cm-2 shear stress using fluid reservoirs as previously reported [328].  
For the first 24 hours, “bead seeding medium” was perfused through channels to promote 
microvessel formation.  Then, experimental media were perfused for 6 days.   
4.2.9.Hierarchical model 
A hierarchical microvascular model was fabricated based on a previously reported model using 
HUVECs [340].  Two template 150 μm diameter super-elastic nitinol wires were suspended with a 
separation distance (d) of 100 – 200 μm.  Microvessels were perfused at 2 dyne cm-2 shear stress.  










Matrigel, perfused with basal media + 20 ng mL-1 bFGF for 5 days.  To assess barrier function, 2 
μM 500 kDa dextran (Thermo Fisher) was perfused through microvessels for thirty minutes before, 
during, and after anastomosis.  Phase contrast and fluorescence images were acquired every two 
minutes, as previously reported [328].  ImageJ was used to plot fluorescence intensity over time, 
where permeability is calculated as (r/2)(1/ΔI)(dI/dt)0, where r is the microvessel radius, ΔI is the 
jump in total fluorescence intensity upon luminal filling, and (dI/dt)0 is the rate of increase in total 
fluorescent intensity over one hour [216, 300]. 
4.2.10.Statistical Analysis 
Statistical testing was performed using Prism ver. 8 (GraphPad).  Measures are reported as mean ± 
standard error of the mean (SEM).   A one-way analysis of variance (ANOVA) test was used for 
comparison of three or more groups.  Reported p-values were multiplicity adjusted using a Tukey 
test.  Differences were considered statistically significant for p < 0.05, with the following 
thresholds: * p < 0.05, ** p < 0.01, *** p < 0.001. 
4.3.Results 
4.3.1.Fabrication of a three-dimensional model of brain angiogenesis 
To assess the angiogenic potential of iPSC-derived brain microvascular endothelial cells 
(dhBMECs), we adapted the bead angiogenesis assay [327].   dhBMECs were differentiated from 
the WTC iPSC line with a fluorescently-tagged plasma membrane (Figure 4-1, A-B).  Beads were 
coated with extracellular matrix (ECM) proteins collagen IV and fibronectin, and then incubated 
with dhBMECs for 2 hours to achieve a uniform coating (Figure 4-1, C-D).  Beads were cultured 
for 24 hours to enable the formation of a confluent monolayer of dhBMECs (BBB beads).  The 
beads were then embedded within extracellular matrix (ECM) to study chemical and physical cues 
that guide angiogenesis.  An entire six-well plate of dhBMECs is sufficient for coating ~12,000 











Figure 4-1. Three-dimensional iPSC model of brain angiogenesis.  (a) Schematic timeline of 
the differentiation of human induced pluripotent stem cell (hiPSC) into brain microvascular 
endothelial cells (dhBMECs) using sequential treatments with mTESR1, UM/F- and RA media 
(composition defined in Methods) over ten days on Matrigel-coated plates.  (b) Phase contrast / 
epifluorescence overlays corresponding to steps shown in Fig. 1a.  WTC iPSC line with RFP-
tagged plasma membrane was used.  (c) Schematic timeline of the bead angiogenesis assay showing 
multiplexed coating of beads with collagen IV (Cn IV) and fibronectin (Fn), seeding with 
dhBMECs, formation of blood-brain barrier (BBB) beads, embedding of BBB beads into 
extracellular matrix (ECM), and treatment with angiogenic stimuli. (d) Phase contrast / 
epifluorescence overlays corresponding to steps shown in Fig. 1c.  
 
Beads coated with dhBMECs display expression of key BBB and endothelial markers, including 
claudin-5, occludin, glucose transporter 1 (GLUT1), p-glycoprotein (Pgp), and CD31 (Figure 4-2, 
A), as previously reported in 2D assays [194, 196, 197].  Protein expression of BBB markers was 
unique to dhBMECs, while the endothelial marker (CD31) was also expressed by human umbilical 
vein endothelial cells (HUVECs) (Figure 4-3).  Additionally, BBB beads express the critical 
angiogenic ligand receptors fibroblast growth factor receptor 2 (FGFR2), vascular endothelial 










B).  Since tight junction proteins (claudin-5 and occludin) restrict paracellular transport into the 
brain, barrier function was assessed by incubating beads in Lucifer yellow (LY) for 3 hours (Figure 
4-2, C).  Three conditions were tested: (1) blank beads (no dhBMECs) without LY, (2) blank beads 
with LY, and (3) beads with a dhBMEC monolayer with LY.   The core of the beads is comprised 
of a permeable dextran polymer and hence beads without a dhBMEC monolayer showed high 
fluorescence intensity after three hours incubation with LY.  In contrast, beads with a dhBMEC 
monolayer significantly restricted accumulation of solutes within the core (p < 0.001) (Figure 4-2, 
D-E).  Beads with HUVEC monolayers restrict Lucifer yellow accumulation less than dhBMECs 
(p = 0.028), consistent with previous studies showing that dhBMECs display at least 10-fold lower 
permeability compared to HUVECs [300, 341] (Figure 4-4, A).   
4.3.2.Influence of chemical factors 
To assess the influence of pro-angiogenic factors, we incubated BBB beads in three media 
conditions: (1) basal media, (2) basal media + 20 ng mL-1 bFGF, and (3) basal media + 20 ng mL-
1 bFGF + 50 ng mL-1 VEGF + 50 ng mL-1 wnt7a.  Across these conditions, the BBB beads were 
embedded within 6 mg mL-1 collagen I hydrogels.   In the absence growth factors, angiogenic 
behavior was not widely observed (Figure 4-5, A): after six days, only 10% of beads displayed 
visible sprouts (Figure 4-5, B).  In the presence of bFGF alone, some angiogenic behavior was 
observed.  The angiogenic fraction and maximum sprout lengths were increased compared to beads 
cultured in the absence of bFGF (p = 0.026 and p = 0.013, respectively), while sprout density was 
not statistically different (p = 0.097) (Figure 4-5, B-D).  The addition of VEGF and wnt7a produced 
on average higher angiogenic phenotype (Figure 4-5, A), which was increased compared to basal 
conditions (p = 0.004, 0.012, and 0.018, respectively), but not statistically significant compared to 
bFGF exposure alone (Figure 4-5, B-D).  The average sprout length for beads in VEGF and wnt7a 











Figure 4-2. Characterization of BBB beads: protein expression and function. (a) Confluent 
monolayers of dhBMECs on 150 μm diameter beads express localized tight junction proteins 
(occludin and claudin-5), the glucose transporter-1 (GLUT1) nutrient transporter, the p-
glycoprotein (Pgp) efflux pump, and endothelial markers (CD31).  (b) BBB beads express receptors 
for basic fibroblast growth factor (FGFR2), vascular endothelial growth factor (VEGFR2), and 
wnt7a (GPR124).  Beads were incubated in 200 μM Lucifer yellow (LY) for 3 hours.  Three 
conditions were tested: (1) blank beads without LY, (2) blank beads with LY, and (3) beads with 
dhBMEC monolayers with LY.  (c) Quantification of LY fluorescence in a circular region of 
interest (ROI) within the beads using confocal microscopy (shown is corresponding phase contrast 
image).    (d) Comparison of normalized fluorescence across conditions (N = 3). (e) Normalized 
fluorescence images for each condition; beads with dhBMECs significantly restrict accumulation 
of LY.  dhBMECs were generated from the plasma membrane (PM) RFP-tagged WTC iPSC line.  












Figure 4-3. Comparison of protein expression between dhBMECs and HUVECs.  Beads were 
coated with dhBMECs or HUVECs and stained for various BBB and endothelial markers.   
HUVEC beads share expression of CD31 with dhBMEC beads, but do not express other canonical 





Figure 4-4. Comparison of phenotype and angiogenic behavior on beads with confluent 
monolayers of dhBMECs or HUVECs.  (a)  Percentage accumulation of Lucifer yellow within 
beads containing cell monolayers relative to beads without cell monolayers for both cell types.  (b) 
Beads display identical appearances before embedding within hydrogel.  After 6 days, HUVECs 
display lower sprout density but higher sprout length were embedded within 6 mg mL-1 collagen I 
hydrogels and supplemented with basal media + 20 ng mL-1 bFGF + 50 ng mL-1 VEGF + 50 ng 












Figure 4-5.  Influence of chemical factors on dhBMEC angiogenesis.  Three media conditions 
were tested: (1) basal media, (2) basal media + 20 ng mL-1 bFGF, and (3) basal media + 20 ng mL-
1 bFGF + 50 ng mL-1 VEGF + 50 ng mL-1 wnt7a.  Across these conditions, dhBMEC beads were 
embedded within 6 mg mL-1 collagen I hydrogels.  (a) Representative images of beads on day 2, 4 
and 6 after embedding in hydrogels.  Sprouts are marked with red asterisks.  (b-d) Angiogenic 
fraction, sprout density and maximum sprout length quantified across conditions on day 6.  (e) Plot 
of maximum sprout length over time for treatment with basal media + 20 ng mL-1 bFGF + 50 ng 
mL-1 VEGF + 50 ng mL-1 wnt7a.  (f) Confocal image of angiogenic processes at day 6 in basal 
media + 20 ng mL-1 bFGF + 50 ng mL-1 VEGF + 50 ng mL-1 wnt7a.   The image is a maximum 
intensity projection over a depth of 240 μm, with inset demonstrating a lumen-like structure.  The 
dotted circle represents the border of the bead; the dotted line represents the location of the cross-
section shown in the inset. Data obtained from N = 5 rounds of the bead assay from unique 











Figure 4-6. Individual contributions of VEGF and wnt7a to angiogenic behavior.  For each 
condition dhBMEC beads were embedded within 6 mg mL-1 collagen I hydrogels and then exposed 
to basal media + 20 ng mL-1 bFGF with additional: (1) 50 ng mL-1 wnt7a, (2) 50 ng mL-1 VEGF, 
or (3) 50 ng mL-1 VEGF + 50 ng mL-1 wnt7a. (a-c) Angiogenic fraction, sprout density and 
maximum sprout length quantified across conditions on day 6.  Data obtained from N = 5 rounds 
of the bead assay from unique differentiations, with greater than 5 technical replicates per 
differentiation.  * p < 0.05.  
 
Confocal imaging of BBB beads cultured in VEGF and wnt7a showed extensive networks of 
angiogenic sprouts and formation of lumen-like structures (Figure 4-5, F).  Sprouts on the BBB 
beads appear predominately comprised of tip cells, while sprouts on HUVEC beads were longer 
(albeit less dense) and appeared to develop tip and stalk cell appearances (Figure 4-4, B).  We also 
analyzed the individual contributions of VEGF and wnt7a compared to the combination of these 
two angiogenic factors (Figure 4-6).  The predominant contributor to angiogenic behavior was 
VEGF, which displayed similar angiogenic fractions and maximum sprout lengths compared to the 
combination (p = 0.990 and 0.921, respectively).  However, sprout density most widely varied 
between these conditions, with wnt7a and VEGF synergistically producing the highest sprout 
density compared to wnt7a alone (p = 0.030).  
4.3.3.Influence of extracellular matrix components 
To assess the role of matrix composition, we tested four ECM conditions: (1) 6 mg mL-1 collagen 
I, (2) 6 mg mL-1 collagen I + 1.5 mg mL-1 growth factor reduced Matrigel, (3) 6 mg mL-1 collagen 
I + fibronectin, and (4) 6 mg mL-1 collagen I + fibrin.  Matrigel is predominately comprised of 
laminin, along with other ECM components [342].  Across these conditions, beads were exposed 










composition (without dramatically altering hydrogel biomechanics) had a less dramatic effect on 
angiogenic phenotype compared to soluble angiogenic factors:  a similar sprouting morphology 
were observed across the conditions (Figure 4-7, A).  The angiogenic fraction was similar across 
additions of ECM components and significant differences were not observed (p > 0.05 for all 
comparisons) (Figure 4-7, B).  Matrigel supplementation led to increased sprout compared to 
fibronectin, suggesting that these two ECM conditions represent the most and least pro-angiogenic, 
respectively (p = 0.03) (Figure 4-7, C).  Maximum sprout length was generally increased in 
response to the addition of ECM components, but was not significantly different (p > 0.05 for all 
comparisons) (Figure 4-7, D).  For all subsequent experiments collagen I was supplemented with 
Matrigel to model angiogenic phenotype. 
 
 
Figure 4-7. Influence of extracellular matrix components on dhBMEC angiogenesis.  Four 
ECM conditions were tested: (1) 6 mg mL-1 collagen I, (2) 6 mg mL-1 collagen I + 1.5 mg mL-1 
fibrin, (3) 6 mg mL-1 collagen I + 1.5 mg mL-1 Matrigel, (4) 6 mg mL-1 collagen I + 0.5 mg mL-1 
fibronectin.  Across these conditions, a combination of bFGF, VEGF and wnt7a were applied 
(media condition #3).  (a) Representative images of dhBMEC beads on day 6 after embedding in 
hydrogels, across conditions.  (b-d) Angiogenic fraction, sprout density, and maximum sprout 
length quantified across conditions on day 6.  Data obtained from N = 5 rounds of the bead assay 











4.3.4.Modeling pathological angiogenesis 
To model pathological brain angiogenesis, we exposed the BBB beads to high and low 
concentrations of hydrogen peroxide (H2O2) in the absence of external growth factor stimuli.   H2O2 
induces production of reactive oxygen species (ROS), whose levels are elevated during 
neurodegenerative disease, brain cancer, and stroke [343].  After two days exposure to 10 μM H2O2, 
the formation of sprouts into the ECM highlights an increased angiogenic phenotype (Figure 4-8, 
A).  The sprout density was significantly increased compared to vehicle treatment (p = 0.047) 
(Figure 4-8, B).  Interestingly, the pro-angiogenic effects of 10 μM H2O2 were not maintained over 
time as by day 6 angiogenic behavior was lost, while vehicle treatment displays minor angiogenic 
behavior (Figure 4-8, C).  This suggests that 10 μM H2O2 exerts a bimodal effect of angiogenic 
phenotype.  Interestingly, the addition of 100-fold higher H2O2 (1 mM) abrogates angiogenic 
behavior on much shorter time scales (no sprouts are observed) (Figure 4-8, A-C).   At this 
concentration cell fluorescence was gradually lost, suggesting progressive cell death, while at all 
other conditions fluorescence was maintained over six days (data not shown). 
 
 
Figure 4-8. Influence of oxidative stress on dhBMEC angiogenesis.  dhBMEC beads were 
exposed to vehicle (H2O), 10 μM, and 1 mM hydrogen peroxide (H2O2) after embedding into 
collagen I + Matrigel hydrogels supplemented with basal media. (a) Phase contrast images of 










sprout density across conditions.  (c) Time course of angiogenic fraction across conditions.  Data 
obtained from N = 4 rounds of the bead assay from unique differentiations, with greater than 5 
technical replicates per differentiation. * p < 0.05, ** p < 0.01. 
 
4.3.5.Perfusable microvessel models of brain angiogenesis 
Next, we tested the role of chemical cues for in vitro dhBMEC angiogenesis within a tissue-
engineered perfusable microvessel model.  These experiments mimic techniques previously 
demonstrated to study angiogenesis from an existing three-dimensional microvessel [340, 344, 
345].  Microvessels were formed in 150 μm diameter channels within 6 mg mL-1 type I collagen 
supplemented with 1.5 mg mL-1 Matrigel (Figure 4-9, A-B).  Channels were seeded with 
dhBMECs, which under continual ~2 dyne cm-2 perfusion, assembled into BBB microvessels, as 
previously reported [300].  After microvessel formation, we applied media conditions as tested in 
Figure 4-5 to observe angiogenic behavior (Figure 4-9, C).  
 
 
Figure 4-9.  Modeling angiogenesis from tissue-engineered brain microvessels.  (a-b) 
Schematic illustrations showing front and side views of model fabrication. Angiogenic factors are 
introduced after microvessel formation (one day after seeding BMECs) to promote sprouting.  (c) 
Phase contrast and fluorescence image overlays of fabrication process.  (d) Phase contrast and 
fluorescence image overlays of representative microvessels perfused with media conditions 










Under perfusion with basal media, angiogenic behavior was not widely observed and the 
microvessel structure remained stable over six days (Figure 4-9, D).  Supplementation with bFGF 
resulted in early sprouts within two days, which continued to grow in length and branching 
complexity (Figure 4-9, D).  Supplementation with bFGF, VEGF, and wnt7a resulted in an 
increased density of sprouts along microvessels after two days, and chaotic sprouting behavior by 
six days (Figure 4-9, D).  Both growth factor supplementation regimes were associated with loss 
of microvessel perfusion after 5 - 6 days due to overgrowth and constriction of microvessel lumens. 
Based on these results we chose to further explore bFGF supplementation over four days to promote 
formation of organized microvascular lumens. 
4.3.6.Hierarchical model of the human blood-brain barrier 
Lastly, we sought to engineer a hierarchical model of the human brain microvasculature by 
promoting sprouting between adjacent BBB microvessels.  This technique has previously been 
demonstrated using HUVECs [340].  We patterned adjacent 150 μm diameter channels within 6 
mg mL-1 type I collagen supplemented with 1.5 mg mL-1 Matrigel separated by 100 – 200 μm 
(Figure 4-10, A-B).  After microvessel formation, microvessels were perfused at ~2 dyne cm-2 with 
basal media + 20 ng mL-1 bFGF (Figure 4-10, C).  Continual perfusion over three days resulted in 
linking of sprouts between microvessels (Figure 4-10, D).    
While angiogenesis and BBB formation are simultaneous during development [73], during 
adulthood brain angiogenesis is typically associated with BBB breakdown [151, 346, 347].  Here, 
we observed that both microvessels and perfusable capillaries restricted transport of 500 kDa 
dextran, providing evidence that lumens formed between microvessels maintain barrier function 
(Figure 4-10, E).  Perfusable lumens were typically 20 – 30 μm in diameter, while smaller diameter 
connections between microvessels did not routinely display lumens (Figure 4-10, F).  Further 











Figure 4-10. Hierarchical model of the BBB via angiogenesis between existing tissue-
engineered brain microvessels. (a-b) Front and side view schematics of hierarchical model of 
brain angiogenesis.  (c) Flow system under to control perfusion of hierarchal model.  (d) Phase 
contrast and fluorescence image overlays of hierarchical capillary network formation.  After 
formation in basal media, microvessels are perfused at 2 dyne cm-2 with 20 ng mL-1 bFGF to 
promote anastomosis of sprouts.  Anastomosed capillaries are visible after 3 days.  (e) Hierarchical 
model perfused with 500 kDa dextran for one hour.  No leakage of dye was observed indicating 
that capillaries were intact and preserved barrier function.  (f) Confocal imaging of capillary lumen 
perfused with 500 kDa dextran.  (g) Confocal imaging of glucose transporter-1 (GLUT1) nutrient 
transporter.  Confocal images are shown at a specific z-plane, with the xz cross-section denoted as 










this model.  As BBB formation is induced via GLUT1 expression during development [71], we 
stained angiogenic processes to confirm robust expression of GLUT1 similar to that of parental 
microvessels (Figure 4-10, G).   
4.4.Discussion 
4.4.1.Factors that regulate in vitro brain angiogenesis  
The formation of brain capillaries during development occurs through the convergence of multiple 
signaling pathways [6, 7, 348].  Vascular endothelial growth factor (VEGF) released by the 
developing neural tube initiates formation of the perineural vascular plexus (PNVP) via 
vasculogenesis.  From the PNVP, BMECs invade the brain parenchyma via angiogenesis driven by 
chemical cues released by developing neurons (e.g. wnt7a/b) and mechanical interactions with the 
brain parenchyma [6, 7, 348].  The culmination of brain angiogenesis during development results 
in a hierarchical BBB with profound heterogeneity in structure and phenotype [230, 347, 349].  
However, after development, angiogenesis is generally restricted to pathological conditions which 
alter BBB structure and phenotype [151, 346, 347].  Here we developed an in vitro model of brain 
angiogenesis using iPSC-derived BMECs (dhBMECs) to study brain angiogenesis.  We explored 
multiple factors that alter angiogenic phenotype of brain microvascular endothelial cells, including 
growth factors, ECM composition, and oxidative stress.    
Critical chemical cues implicated in developmental brain angiogenesis include vascular endothelial 
growth factor (VEGF) [70] and wnt7a/b (WNT) [71].  WNT signaling is specifically required for 
brain angiogenesis and is harnessed during differentiation of hiPSC-derived BMECs [194].  
However, other growth factors, including basic fibroblast growth factor (bFGF), are also implicated 
in promoting brain angiogenesis [350, 351].  Here we found that all three growth factors are likely 
pro-angiogenic for dhBMECs.  In previous studies of primary brain microvascular endothelial cells 










insufficient to promote formation of new vessels.  In contrast, we found that angiogenic factors are 
sufficient to promote angiogenesis of dhBMECs within a 3D microenvironment, supporting the 
development of more physiological angiogenesis models.  
Additionally, ECM composition and stiffness are key regulators of angiogenesis [352-355].  
Numerous studies have shown that increased ECM stiffness reduces angiogenesis, likely by 
limiting cell proliferation and migration [354, 355].  Pro-angiogenic ECM proteins include collagen 
I, fibronectin, and laminin [352].  In studies specific to BMECs, fibronectin and laminin were 
shown to promote angiogenic and maturation phenotype, respectively [356].  The extracellular 
space in the brain is comprised of hyaluronic acid, lecticans, proteoglycan link proteins, and 
tenascins [357, 358].  However, as the human brain is highly cellular by volume, non-brain-specific 
ECM components are commonly used to mimic the physical properties of the brain in vitro  [26, 
359, 360].  For example, 3D BBB models commonly utilize non-brain ECM components including 
collagen I [186-189, 300, 361] and fibrin [180, 209, 336, 362].  We previously characterized and 
compared the stiffness of collagen I hydrogels to native mouse brain, and showed that 6 mg mL-1 
collagen is a reasonable proxy for brain stiffness [328].  Additionally, materials with stiffnesses 
much lower than native brain were not conducive to the formation of stable BBB microvessels 
[328].  Thus, we chose to only explore ECM materials with sufficient stiffness to form perfusable 
microvessel models, despite their absence within the brain parenchyma.  We found that addition of 
growth factor-reduced Matrigel (primarily composed of laminin) to a collagen I matrix increased 
angiogenic phenotype.  Interestingly, fibronectin which plays a critical role in vivo, was not found 
to alter sprouting in vitro; this could result from differences in integrin expression on dhBMECs, 
use of suboptimal fibronectin concentrations, or differences in other microenvironmental variables.  
Higher concentrations of fibronectin were not tested as they required substantial alteration of bulk 










Under homeostatic conditions angiogenesis is not prevalent in the adult brain, however, brain 
angiogenesis is associated with pathological conditions, including neurodegenerative disease, brain 
cancer, and stroke [347].  Production of reactive oxygen species (ROS) is associated with these 
conditions and may contribute to BBB disruption and pathological angiogenesis [343].  Reactive 
oxygen species promote angiogenesis via both VEGF-dependent and independent mechanisms 
[363].  Previous work utilizing primary rat BMECs found that H2O2 displays a concentration-
dependent influence on angiogenic behavior: concentrations below 10 μM increased tube length in 
a Matrigel tube formation assay, while concentrations above 10 μM decreased tube length [325].  
Here, the use of BBB beads provides spatial and temporal resolution to study the time-dependent 
effects of oxidative stress, which have previously been ignored.  We found that H2O2 exerts a 
bimodal and concentration-dependent effect on brain angiogenesis.   
4.4.2.Model advantages and limitations 
2D models of brain angiogenesis (i.e. transwell assay or Matrigel tube forming assay) are unable 
to recapitulate the spatial dynamics of BMEC sprouting.  Recently, 3D models of the brain 
microvasculature have been engineered via mimicry of vasculogenesis or angiogenesis using co-
cultured primary ECs or BMECs, pericytes, and astrocytes [180, 209, 336].  Additionally, a 
microfluidic model of neurogenesis and angiogenesis was formed using co-cultured mesenchymal 
stem cells, primary BMECs, and neural stem cells, but was not tested for functional BBB properties 
[362].  While hiPSC-derived BMECs have been used to create microfluidic co-culture models of 
the BBB [332], this platform is not conducive for mimicking brain angiogenesis. 
The bead assay incorporates a confluent monolayer of dhBMECs on a polymer bead which can be 
used in suspension or embedded in a matrix.  Since there are no boundaries to the monolayer, this 
geometry avoids the perimeter effect associated with transwell assays.  Furthermore, the bead assay 










visualization of the endothelium.  This model supports controlled studies of microenvironmental 
cues and genetic mutations on angiogenesis, without confounding factors present in vivo. 
Additionally, previous models have utilized fibrin for creating brain microvascular networks via 
angiogenesis and vasculogenesis-like processes [180, 209, 336].  Although neither collagen I nor 
fibrin is found in native brain ECM, collagen I densities used in this study are similar to the 
mechanical stiffness of native brain.    
There are two main limitations to our model. (1) Brain angiogenesis in vivo occurs in the presence 
of complex cell-cell interactions, which are neglected in our model:  BMECs interact with neurons, 
neural progenitor cells, pericytes, and glial progenitors during brain angiogenesis.  As previously 
discussed, neurons and neural progenitor cells release critical chemical stimuli including wnt 
ligands and VEGF, which we introduce to promote sprouting in our model.  Pericytes are an 
important cellular component of the neurovascular unit as they physically support new capillaries 
and are required for the formation of the BBB during development [231, 364].  Astrocytes are not 
critically involved in angiogenesis, as they are not present during initial brain vascularization; 
however, postnatally, they release ligands that maintain BBB integrity [76].   Lastly, radial glial 
cells guide spatial patterning of angiogenesis as a physical scaffold for endothelial cell migration 
[7, 365].  Recent reports of an isogenic multicellular iPSC-based BBB transwell assay provide the 
foundations for building more complex angiogenesis models [366].  Additionally, we previously 
incorporated iPSC-derived pericytes into a 3D microvessel BBB model, showing that they do not 
significantly alter barrier properties [320].  Future work is required to examine how iPSC-derived 
pericytes and other cells of the BBB may alter angiogenesis in vitro.  (2) The stability of angiogenic 
vessels is not addressed: the adult cerebrovasculature is highly stable, with limited angiogenesis 
[347].  For example, over 30 days changes in capillary length, diameter or branching were not 










cerebrovasculature should aim to mimic physiological structural and phenotypic stability.  We 
previously explored the stability of BBB microvessels, finding that microvessels reach quiescence 
over several days (when rates of cell division match cell apoptosis) [300].  However, the stability 
of microvessels formed via angiogenesis has not been addressed.  As growth factor expression can 
display unique temporal and spatial expression patterns [70], transient administration or removal 
of growth factors may aid in generating stable microvessels.  Future work will explore how removal 
of growth factors after angiogenesis occurs alters the structural and phenotypic stability of tissue-
engineered cerebrovascular models.  Additionally, many other stimuli influence the morphology of 
microvasculature in vitro, including flow and shear stress [353, 367], which could be harnessed to 
promote stability.  
4.4.3.Engineering BBB hierarchy 
To promote sprouting and anastomosis of capillaries between adjacent tissue-engineered 
microvessels we applied angiogenic factors which maximized growth rates.  In previous work, 
capillary growth rates of  ~40 μm day-1 were sufficient to anastomose adjacent HUVEC 
microvessels [340].  Here we observed more modest growth rates for dhBMECs (~20 μm day-1).  
Previously it has been found that iPSC-derived endothelial cells exhibit reduced angiogenic 
potential compared to primary ECs (HUVECs), likely due to differences in MMP production [368].  
Due to limitations with primary and immortalized BMEC sources we did not explore cell source-
dependent angiogenic differences.  Importantly, our hierarchical model allows probing of how BBB 
phenotype changes across the vascular tree.  Recently, we demonstrated use of BBB microvessels 
for studying hyperosmotic BBB disruption [282], but do not know if capillaries are more 











Existing in vitro models have generally failed to mimic brain angiogenesis or recapitulate 
physiological barrier function, hierarchy, and zonation of the human BBB.  Here, we develop 3D 
in vitro stem cell-based models of brain angiogenesis, including a high-throughput BBB bead assay 
and perfusable microvessel model.  These models have diverse applications in screening the 
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